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Heterogeneous activated fibroblasts that deposit and remodel extracellular matrix (ECM) comprise
desmoplasia, a key regulator of tumor development. The divergent outcomes in response to varied therapies
targeting intratumoral desmoplasia underscore the pressing need to delineate the intricate role of a
heterogeneous stroma in tumorigenesis. Fibroblast activation protein (FAP) and alpha-smooth muscle actin
(αSMA) identify distinct, yet overlapping, activated fibroblast subsets in myriad tumor types, fibrosis, and
wound healing. FAPHi reactive fibroblasts and αSMAHi myofibroblasts can exert divergent influences on
tumor progression. However, the factors that drive this phenotypic heterogeneity and the unique functional
roles of these distinct phenotypes are not yet understood. By comparing fibroblast activation on fibronectin-
and collagen I-coated hydrogels of varying stiffness, I demonstrated that a convergence of ECM composition,
elasticity, and TGF-β signaling governs activated fibroblast phenotypic heterogeneity. Furthermore, by
characterizing gene expression signatures, I revealed potentially unique roles of activated fibroblast subsets in
tissue remodeling.
In addition to its utility as a marker of activated fibroblasts, FAP also constitutes a highly attractive drug target
due to its selective expression in the tumor microenvironment and its pro-tumorigenic proteolytic activity.
FAP-mediated proteolysis of collagen I and III fragments promotes collagen clearance. However, the potential
mechanistic link between FAP’s role in collagen proteolysis and tumorigenesis is not yet known. I investigated
the role of FAP-dependent collagen proteolysis and ECM remodeling in tumorigenesis using both a
spontaneous oncogenic Kras-driven lung tumor model and fibroblast-derived matrices. I found that Fap
genetic deletion promotes intratumoral fibrillar collagen accumulation and attenuates lung tumor multiplicity,
size, progression, and proliferation. Furthermore, I obtained preliminary evidence that Fap-/- lung fibroblasts
produce ECM with enhanced fibrillar collagen accumulation, which directly impedes both tumor cell
proliferation and motility. Taken together, my research underscores the essential role of ECM remodeling in
regulating key aspects of tumorigenesis, such as intratumoral fibroblast heterogeneity, proliferation, and
invasion.
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ABSTRACT 
 
EXTRACELLULAR MATRIX REGULATES FIBROBLAST HETEROGENEITY AND 
TUMORIGENESIS 
Diana Avery 
Ellen Puré 
 
Heterogeneous activated fibroblasts that deposit and remodel extracellular matrix 
(ECM) comprise desmoplasia, a key regulator of tumor development. The divergent 
outcomes in response to varied therapies targeting intratumoral desmoplasia underscore 
the pressing need to delineate the intricate role of a heterogeneous stroma in 
tumorigenesis. Fibroblast activation protein (FAP) and alpha-smooth muscle actin 
(αSMA) identify distinct, yet overlapping, activated fibroblast subsets in myriad tumor 
types, fibrosis, and wound healing. FAPHi reactive fibroblasts and αSMAHi myofibroblasts 
can exert divergent influences on tumor progression. However, the factors that drive this 
phenotypic heterogeneity and the unique functional roles of these distinct phenotypes 
are not yet understood. By comparing fibroblast activation on fibronectin- and collagen I-
coated hydrogels of varying stiffness, I demonstrated that a convergence of ECM 
composition, elasticity, and TGF-β signaling governs activated fibroblast phenotypic 
heterogeneity. Furthermore, by characterizing gene expression signatures, I revealed 
potentially unique roles of activated fibroblast subsets in tissue remodeling.  
In addition to its utility as a marker of activated fibroblasts, FAP also constitutes a 
highly attractive drug target due to its selective expression in the tumor 
microenvironment and its pro-tumorigenic proteolytic activity. FAP-mediated proteolysis 
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of collagen I and III fragments promotes collagen clearance. However, the potential 
mechanistic link between FAP’s role in collagen proteolysis and tumorigenesis is not yet 
known. I investigated the role of FAP-dependent collagen proteolysis and ECM 
remodeling in tumorigenesis using both a spontaneous oncogenic Kras-driven lung 
tumor model and fibroblast-derived matrices. I found that Fap genetic deletion promotes 
intratumoral fibrillar collagen accumulation and attenuates lung tumor multiplicity, size, 
progression, and proliferation. Furthermore, I obtained preliminary evidence that Fap-/- 
lung fibroblasts produce ECM with enhanced fibrillar collagen accumulation, which 
directly impedes both tumor cell proliferation and motility. Taken together, my research 
underscores the essential role of ECM remodeling in regulating key aspects of 
tumorigenesis, such as intratumoral fibroblast heterogeneity, proliferation, and invasion. 
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CHAPTER ONE: INTRODUCTION 
The analogy between tumor stroma generation and wound healing 
Heterogeneous activated fibroblasts that deposit and remodel extracellular matrix 
(ECM) comprise desmoplasia, a key regulator of tumor development. Tumor stroma 
resembles granulation tissue to such an extent that many researchers characterize 
tumors as “wounds that never heal” or “overhealing wounds”1–4. Of particular relevance, 
both intratumoral desmoplasia and granulation tissue evolve from a provisional fibrin- 
and fibronectin (FN)-rich ECM into mature collagenous ECM1 (Fig. 1). Bidirectional 
regulatory mechanisms between activated fibroblasts and ECM orchestrate this 
transition. Activated fibroblasts are identified by diverse markers, such as alpha smooth 
muscle actin (αSMA), fibroblast activation protein (FAP), platelet-derived growth factor 
receptor-β (PDGFRβ), PDGFRα, prolyl 4-hydroxylase, and discoidin domain-containing 
receptor 25,6.  Thus far, most research has focused on the mechanisms that drive 
αSMAHi myofibroblast differentiation. ECM stiffness, growth factors (in particular, TGF-β), 
and ECM components (such as EDA-FN) collectively promote myofibroblast 
differentiation7–10. However, the regulatory mechanisms that govern generation of other 
activated fibroblast subsets remain mostly undefined.   
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Figure 1. Analogous evolution of ECM composition in wound healing and 
tumorigenesis.  
In acute injury, plasma extravasation from damaged blood vessels forms a FN-rich 
provisional matrix. Highly permeable tumor microvasculature similarly promotes plasma 
FN deposition. In both granulation tissue and tumors, activated fibroblasts gradually 
replace provisional FN-rich ECM with mature, collagenous ECM.   
 
 FAP: Structure and function 
FAP is a marker of a subset of activated fibroblasts in the injury response11, 
fibrotic and inflammatory conditions12–14, and myriad tumor types15–19. Of all the members 
of its prolyl peptidase subfamily (S9B) of serine proteases, FAP shares highest amino 
acid sequence homology (~50%) with dipeptidyl peptidase IV (DPPIV)20,21. Based on its 
amino acid sequence, FAP exhibits the structural features of a cell surface type II 
integral membrane protein, with a short cytoplasmic tail, a transmembrane segment, and 
a large extracellular domain20. X-ray crystallography illustrated that FAP resides at the 
cell surface as a homodimer. Each extracellular subunit of the FAP homodimer contains 
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a seven-bladed β-propeller domain that overhangs an α/β hydrolase domain (Fig. 2). 
The FAP catalytic triad, composed of residues Ser624, Asp702, and His734, resides at 
the interface of these two domains22. 
 
Figure 2.  FAP functional domains. 
Cytoplasmic domain (Cyto; yellow); transmembrane domain (TM, black); linker region 
(red); β-propeller domain (blue); catalytic domain (green).   
 
FAP functions not only as a dipeptidyl peptidase, but also an endopeptidase, 
which distinguishes it from all other members of its prolyl peptidase subfamily18,20,22. No 
study has yet definitively determined the physiologic substrates of FAP. However, recent 
in vitro evidence has implicated type I and III collagen fragments as FAP substrates. The 
in vitro digest of collagen by FAP requires prior cleavage by matrix metalloproteinase-1 
(MMP-1). Subsequently, FAP digests the resulting ¼ -C-terminal and ¾ -N-terminal 
collagen fragments into smaller peptides23 (Fig. 3). Further corroborating FAP as a 
mediator of collagen catabolism, FAP enzymatic activity expedites collagen turnover24. 
Therefore, FAP deficiency exacerbates collagen accumulation in murine models of lung 
cancer and fibrosis24,25. Additional putative substrates of FAP endopeptidase activity 
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include FGF2126–28 and α2-antiplasmin23, implicating FAP as a regulator of metabolism 
and fibrinolysis, respectively.  
 
 
Figure 3. FAP plays a role in the ordered proteolytic processing of collagen. 
The digest of fibrillar collagen (I or III) by FAP requires prior cleavage by MMP 
collagenases. Subsequently, FAP (in conjunction with other gelatinases) digests the 
resulting ¼ -C-terminal and ¾ -N-terminal collagen fragments into smaller peptides.  
 
FAP as a therapeutic target in the tumor microenvironment 
Among the array of secreted and cell surface proteases in the tumor 
microenvironment, FAP constitutes a highly attractive therapeutic target for several 
reasons. First, its low levels of expression in most normal adult tissue and selective 
expression on carcinoma-associated fibroblasts (CAFs) minimize the likelihood of 
adverse events due to on-target, off-tumor effects of FAP-targeted therapies. Second, its 
expression on the cell surface of CAFs and its proteolytic function render it amenable to 
targeting via diverse therapeutic approaches. Third, a variety of murine tumor models 
have demonstrated an active role of FAPHi CAFs and FAP proteolytic activity in the 
promotion of tumorigenesis. Lastly, when assessed clinically, higher FAP expression 
correlated with poorer clinical outcome in myriad solid tumor types, including gastric 
cancer29, colorectal cancer30–33, pancreatic adenocarcinoma34–36, clear cell renal cell 
carcinoma37,38, oral squamous cell carcinoma39, breast cancer40,41, osteosarcoma42, non-
small cell lung cancer43, rectal cancer44, and hepatocellular carcinoma45.  
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FAP and αSMA identify distinct, yet overlapping, activated fibroblast subsets in 
actively remodeling tissues. 
The discovery of FAP has facilitated the identification of heterogeneous subsets 
of activated fibroblasts. After transient expression in some fetal mesenchymal tissues 
during embryonic development46,47, the quiescent mesenchyme of most normal adult 
organs exhibits little or no FAP expression15,18. However, activated fibroblasts exhibit 
high FAP expression in conditions associated with active tissue remodeling, such as the 
injury response11, fibrotic and inflammatory conditions12–14, and myriad tumor types15–19. 
As discussed herein, FAP and αSMA identify spatiotemporally distinct, yet overlapping, 
subsets of activated fibroblasts in virtually all assessed physiological and 
pathophysiological settings.  
FAP and αSMA identify spatially and temporally distinct subsets of activated 
fibroblasts in granulation tissue. In various injury models, FAP expression increases 
relatively rapidly in response to wounding. For example, in response to bleomycin- or 
radiation-induced injury, lungs exhibit near peak Fap gene expression (at least five-fold 
upregulation) as early as 24 hours post-injury24. In contrast, Acta2 (αSMA) gene 
expression remains low at early timepoints after bleomycin-induced lung injury (days 1 
and 3), despite an early increase in Col1a1 gene expression in pulmonary fibroblasts at 
day 348.  Fibroblasts exhibit peak Acta2 expression between days 7 and 14 post-injury48.  
Similarly, in a rat model of myocardial infarction (MI), FAP expression increases at day 3 
and peaks around day 7 post-MI11. Most FAP+ cells show strong co-expression of prolyl-
4-hydroxylase and vimentin, signifying an activated and collagen synthetic fibroblast 
phenotype. However, only a minority of FAP+ fibroblasts co-express αSMA11.  
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Analogous to the expression patterns observed in granulation tissue, FAP and 
αSMA identify overlapping, but spatially distinct fibroblast populations in various fibrotic 
conditions. In liver cirrhosis, stellate cells express high FAP levels in the periseptal area 
of regenerative nodules (the presumptive tissue remodeling interface), but low levels in 
the portal fibrous septa. In direct contrast, stellate cells express virtually no αSMA in 
regenerative nodules, but elevated αSMA levels in the portal fibrous septa13.  
Interestingly, FAP, but not αSMA, expression directly correlates with the severity of liver 
fibrosis and the necroinflammatory score49. In idiopathic pulmonary fibrosis (IPF), 
fibroblast foci at the tissue remodeling interface (areas of ongoing injury and repair) 
similarly exhibit high FAP, but low αSMA, expression. 
Inflammatory conditions similarly exhibit distinct patterns of FAP and αSMA 
expression. For example, in Crohn's disease-associated intestinal fibrosis, collagen-rich 
fibrotic areas show high αSMA, but low FAP, expression. Meanwhile, fibroblasts 
adjacent to fibrotic areas exhibit high FAP expression50. In a comparable fashion, 
smooth muscle cells (SMCs) in human atherosclerotic aortic plaques upregulate FAP 
expression predominantly in collagen-poor regions. In fact, Masson staining for collagen 
and FAP immunohistochemistry (IHC) in adjacent tissue sections demonstrated that 
FAP expression is significantly enhanced in thin-cap (< 65 μm) versus thick-cap (> 65 
μm) human coronary fibroatheromata51.  
These divergent patterns of FAP and αSMA expression also arise during 
tumorigenesis. Reactive stroma exhibits high FAP expression in virtually all 
carcinomas52 as well as melanoma53,54, glioblastoma19, and sarcoma42. Depending on 
tumor type and stage, the degree of overlap between FAP and αSMA varies markedly. 
The spatiotemporal regulation of FAP and αSMA expression in intratumoral stroma has 
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been studied most extensively in pancreatic ductal adenocarcinoma (PDAC). CD45-
PDGFRα+ stromal cells in pancreatic intraepithelial neoplasia express FAP, but rarely 
αSMA55. However, upon progression to PDAC, the frequency of αSMAHi myofibroblasts 
increases55. In human and murine PDAC, intratumoral stroma displays striking 
heterogeneity, including FAPHiαSMALow, FAPLowαSMAHi, and FAPHiαSMAHi activated 
fibroblast subsets16,55–57. Interestingly, analysis of the spatial distribution of these 
fibroblast subsets in human and murine PDAC revealed that FAPHiαSMAHi fibroblasts 
often form periglandular rings surrounding tumor cell nests, while FAPHiαSMALow 
fibroblasts predominantly localize further away from the tumor-stromal interface. Thus, 
stromal cell composition evolves throughout the course of PDAC, akin to the 
spatiotemporal separation of FAPHi and αSMAHi activated fibroblast subsets seen in the 
injury response.   
As in PDAC, both breast and lung cancer microenvironments foster the 
generation of heterogeneous stromal cell populations. In multiple breast cancer subtypes 
(including hormone receptor-positive, HER2/neu-positive, and triple negative breast 
cancer), the majority of stromal cells (~85%) express FAP, while only a minority (~30%) 
express αSMA. Consistent with the spatial distribution seen in PDAC, αSMAHi 
myofibroblasts often localize to concentric rings surrounding EpCAM+ tumor cell nests in 
human breast cancer17. In non-small cell lung cancer (NSCLC), IHC analysis of tumor 
specimens from a large cohort (n=536) of patients demonstrated no correlation between 
FAP and αSMA expression in both lung adenocarcinoma and squamous cell carcinoma, 
indicating that FAP and αSMA identify distinct pulmonary CAF subsets58. Interestingly, a 
thorough characterization of other tumor and stromal cell markers in these same tumor 
specimens illustrated that, of all markers assessed, only collagen (as visualized with 
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Masson’s trichrome staining) positively correlated with αSMA expression. Meanwhile, 
FAP expression and collagen showed no correlation58, coinciding with the expression 
patterns of FAP, αSMA, and collagen in fibrotic and inflammatory disorders as discussed 
above.     
ECM proteolysis, mechanics, and architecture regulate tumorigenesis. 
Importantly, activated fibroblasts synthesize and remodel intratumoral ECM. The 
biochemical, mechanical, and architectural properties of ECM coordinately regulate 
tumor evolution. ECM degradation influences tumorigenesis through a variety of different 
mechanisms. Proteolysis of collagen I can alter integrin engagement by exposing 
matricryptic RGD motifs. For example, β1 and αvβ3 integrins preferentially bind native 
fibrillar collagen and exposed RGD motifs, respectively59,60. This differential integrin 
binding, in turn, can regulate tumor cell behavior. α2β1 ligation of fibrillar collagen 
arrests melanoma cell proliferation61, while αvβ3 ligation of degraded collagen promotes 
melanoma cell survival and proliferation62,63. Collagen proteolysis also promotes cancer 
cell invasion through ECM64,65 and regulates tumor neovascularization by liberating 
latent growth factors (such as VEGF66 and TGF-β67) and releasing type IV collagen-
derived anti-angiogenic fragments68. Furthermore, high and low molecular weight 
hyaluronan (HA; a glycosaminoglycan that accumulates in tumors) exert anti- and pro-
tumorigenic influences, respectively69,70. For example, the extremely high molecular 
mass of HA in naked mole-rats (Heterocephalus glaber) mediates their inherent cancer 
resistance71.  
ECM mechanics also play a fundamental role in tumor evolution. For example, 
lysyl oxidase (LOX)-mediated collagen crosslinking and cytoskeletal contractility both 
heighten intratumoral ECM stiffness, which promotes breast tumor proliferation and 
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invasion via integrin-mediated signaling72–75. High ECM stiffness generated by 
myofibroblast contraction also releases latent growth factors, such as TGF-β76,77. 
Furthermore, tensile forces expose cryptic epitopes in FN (a crucial ECM component of 
the pre-metastatic niche78), which triggers fibrillogenesis79 and promotes cellular 
adhesion80. Lastly, HA deposition augments interstitial fluid pressure, which restricts 
intratumoral drug delivery in PDAC81.    
ECM architecture also directs tumor cell behavior. Collagen organization at the 
tumor-stromal interface regulates invasion, as evidenced by tumor-associated collagen 
signatures that correlate with the degree of murine mammary tumor invasiveness. 
Collagen fibers that align radially from tumors facilitate local tumor growth and 
invasion82. In vitro studies have demonstrated how CAFs orchestrate this pro-invasive 
ECM remodeling. As CAFs invade a type I collagen-rich ECM, they generate aligned 
collagen fibers, via a mechanism dependent on MMP activity and Rho-mediated ECM 
contraction75,83. Carcinoma cells travel along these linear collagen-containing ECM fibers 
at high velocities, as demonstrated via intravital imaging of metastatic primary 
tumors84,85. Moreover, the density and orientation of intratumoral ECM fibers regulates 
antitumor immunity by controlling T cell migration86.  
Intratumoral stroma as a therapeutic target 
Considering the essential role of ECM in tumor evolution, many laboratories have 
developed therapies that target intratumoral desmoplasia. Several therapeutic 
approaches that deplete or target activated stromal cells hinder disease progression in 
pre-clinical models of cancer and fibrosis. For example, depleting FAPHi fibroblasts 
impedes primary and metastatic outgrowth in a variety of different tumor models 
(discussed at length in the next section). Furthermore, the synthetic Vitamin D receptor 
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agonist calcipotriol antagonizes pro-fibrotic TGF-β/SMAD-dependent signaling by 
displacing SMAD3 from the promoters of target genes. In murine models of hepatic 
injury, calcipotriol treatment inhibits hepatic stellate cell activation, and consequently, 
abrogates liver fibrosis87. Calcipotriol treatment also reverts the pro-fibrotic and pro-
inflammatory phenotype of activated pancreatic stellate cells. As a result, adjuvant 
administration of calcipotriol enhances the delivery and efficacy of gemcitabine, slows 
tumor growth, and prolongs survival by 57% compared to gemcitabine monotherapy in 
the LSL-KrasG12D/+; LSL-Trp53R172H/+, Pdx-1-Cre (KPC) model of PDAC88.  
However, not all stroma-targeted therapeutic strategies achieve positive 
outcomes. After finding that paracrine sonic hedgehog (SHH) ligands secreted by 
neoplastic cells promote desmoplasia89,90, a pre-clinical study demonstrated that short-
term treatment with an inhibitor of SHH-mediated signaling (IPI-926; a smoothened 
inhibitor) improves gemcitabine delivery in KPC tumors by decreasing collagen content, 
while increasing intratumoral vascular density91. However, concurrent administration of 
smoothened inhibitors with chemotherapy did not improve survival in clinical trials92. 
Thereafter, follow-up studies discovered that long-term inhibition of SHH signaling 
actually shortens survival of KPC mice93,94. Further analysis demonstrated that while 
inhibition of SHH signaling restrains myofibroblast proliferation, it accelerates epithelial 
cell proliferation, thereby promoting pancreatic intraepithelial neoplasia formation (the 
precursor lesion before the onset of PDAC) and PDAC progression93,94. Around the 
same time, another group found that depletion of proliferating αSMAHi myofibroblasts (via 
systemic ganciclovir administration in αSMA-thymidine kinase transgenic mice) yields 
adverse outcomes in multiple autochthonous murine models of PDAC56. This mode of 
stromal depletion reduces intratumoral stiffness and collagen content; however, FAP-
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expressing fibroblasts remain abundant56. αSMAHi myofibroblast depletion shortens the 
lifespan of KPC mice, likely through its enhancement of epithelial-mesenchymal 
transition, cancer stem cell prevalence, and immunosuppression56. Altogether, the 
dichotomous outcomes in response to varied stroma-targeted therapies emphasize the 
urgent need to delineate the intricate role of a heterogeneous stroma in tumorigenesis. 
Targeting FAPHi stromal cells in cancer 
Taking full advantage of the selective expression of FAP on the cell surface of 
intratumoral stromal cells, several laboratories have successfully curtailed tumor growth 
and metastasis in murine models by depleting FAPHi CAFs via diverse therapeutic 
strategies. Our laboratory demonstrated that FAPHi CAF depletion via FAP-targeted 
chimeric antigen receptor (FAP-CAR) T cells curbs tumor growth in autochthonous and 
transplanted tumor models via immune-dependent and -independent mechanisms. In 
highly immunogenic tumors, FAP-CAR T cells enhance anti-tumor immunity by 
augmenting endogenous CD8+ T cell responses95. In non-immunogenic, but highly 
desmoplastic tumors, FAP-CAR T cells restrain tumor growth by diminishing intratumoral 
vascularization and desmoplasia, including prevalent ECM components, such as FN, 
HA, collagen, and versican29. FAP-targeted vaccines attain similar anti-tumor efficacy. 
FAP-transduced whole-cell tumor vaccines enhance intratumoral CD8+ T cell infiltration 
and suppress proliferation and differentiation of immunosuppressive immune cell 
populations, such as M2 macrophages, myeloid-derived suppressor cells, and regulatory 
T cells96. Vaccination with FAP-transfected dendritic cells or DNA-based FAP vaccines 
suppresses tumor growth, reduces pulmonary metastatic burden, and prolongs survival 
in a variety of transplanted tumor models97,98. Moreover, combining FAPHi CAF depletion 
(FAP-CAR T cells or FAP-targeted vaccines) with chemotherapy achieves additive or 
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synergistic anti-tumor efficacy and prolongs survival16,98,99, in part by increasing 
intratumoral drug uptake98.  
Other laboratories have exploited the unique proteolytic activity of FAP to design 
CAF-targeted prodrugs and protoxins. For example, FAP-activated peptide toxins 
contain FAP-cleavable sequences conjugated to promelittin protoxins. This therapeutic 
approach restricts melittin cytolytic activity mainly to the tumor site, thereby inhibiting 
tumor growth with minimal toxicity to the host animal100. In a similar fashion, FAP-
activated prodrugs achieve comparable anti-tumor efficacy and mitigate toxicity 
compared to commonly used chemotherapeutic agents101–103. Moreover, nanoparticle-
based photoimmunotherapy (nano-PIT) only depletes FAPHi stromal cells at the tumor 
site. This approach features a FAP-specific single chain variable fragment conjugated to 
apoferritin, a compact nanoparticle protein cage used as a photosensitizer carrier. By 
selectively administering photoirradiation at the tumor site, nano-PIT exclusively 
eliminates FAPHi intratumoral CAFs. Comparable to aforementioned FAPHi fibroblast 
depletion strategies, this therapeutic approach enhances intratumoral cytotoxic T cell 
infiltration, suppresses tumor growth, and prolongs survival104.   
Targeting FAP proteolytic activity in cancer 
In addition to its utility as a marker of activated fibroblasts, FAP also constitutes a 
highly attractive drug target due to its selective expression in the tumor 
microenvironment and its pro-tumorigenic proteolytic activity. In our laboratory, we have 
found that FAP accelerates tumor growth and metastasis in a variety of transplanted and 
autochthonous murine tumor models. In an inducible K-rasG12D-driven autochthonous 
murine model of lung cancer, both Fap genetic deletion and pharmacological inhibition of 
FAP enzymatic activity reduced lung tumor burden25. The diminished lung tumor burden 
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in FAP-deficient mice was associated with excess collagen accumulation and 
dysregulated integrin-mediated signaling25. Recent studies also demonstrated that FAP 
cleaves collagen I and III fragments, and that FAP-mediated collagen proteolysis 
promotes collagen clearance23,24. However, the potential mechanistic link between FAP’s 
role in promoting collagen proteolysis and tumorigenesis is not known.  
Dissertation goals 
  Overall, the research described in this dissertation aimed to delineate 
bidirectional regulatory mechanisms between heterogeneous activated fibroblast 
subsets and ECM, and how these features of desmoplasia coordinately regulate 
tumorigenesis. Specifically, the goals of this dissertation were to: 1) identify features of 
actively remodeling tissues that drive FAPHi versus αSMAHi fibroblast activation, 2) 
unravel potentially unique functional roles of FAPHi and αSMAHi activated fibroblasts 
subsets in the tumor microenvironment, and 3) explore the mechanisms by which FAP 
proteolytic activity (especially its role in ECM remodeling) promotes tumor proliferation 
and metastasis.  
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CHAPTER TWO: EXTRACELLULAR MATRIX DIRECTS PHENOTYPIC 
HETEROGENEITY OF ACTIVATED FIBROBLASTS 
 
Introduction     
In development and homeostasis, fibroblasts synthesize extracellular matrix 
(ECM), which regulates cell differentiation and behavior. As sentinel cells, fibroblasts 
respond to injury and neoplasia by differentiating to highly secretory, proliferative, or 
contractile phenotypes. This heterogeneous activated fibroblast population orchestrates 
injury resolution. However, in fibrosis and cancer, the aberrant accumulation of activated 
fibroblasts and ECM disrupts organ function7–10,105. 
Fibroblast activation protein (FAP) is a marker of activated fibroblasts in the injury 
response11, fibrotic and inflammatory conditions12–14, and myriad tumor types15–19. In 
most epithelial-derived tumors, FAP and alpha smooth muscle actin (αSMA; the 
canonical myofibroblast marker) identify distinct, yet overlapping, fibroblast 
subsets16,17,56–58. Importantly, FAPHi fibroblasts and αSMAHi myofibroblasts diverge in 
their impact on tumorigenesis. FAPHi fibroblasts accelerate the growth of multiple tumor 
types by promoting intratumoral desmoplasia, angiogenesis, and 
immunosuppression16,95,106,107. In contrast, αSMAHi myofibroblasts can curb pancreatic 
cancer aggressiveness by restraining epithelial-mesenchymal transition, cancer stem 
cell generation, and immunosuppression56. FAP and αSMA similarly mark distinct 
fibroblast subsets in fibrotic conditions, including idiopathic pulmonary fibrosis and liver 
cirrhosis12,13. However, the conditions regulating this phenotypic heterogeneity and the 
unique functional roles of these phenotypically distinct subsets are not yet known. 
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Disentangling these complexities will clarify the roles of heterogeneous fibroblast 
subsets in physiological and pathophysiological settings.   
ECM composition and mechanics exhibit spatiotemporal heterogeneity in acute 
injury, fibrosis, and cancer108–113. Notably, both granulation tissue and intratumoral 
desmoplasia evolve from elastic, fibronectin (FN)-rich to stiff, collagen I (COL 1)-rich 
ECM1–3,112,114. Therefore, we hypothesized that ECM properties directly regulate 
fibroblast heterogeneity. To test this hypothesis, we assessed fibroblast activation on 
substrata of defined stiffness and composition. Gene expression analysis revealed 
distinct signatures, suggesting unique functional roles of FAPHi fibroblasts and αSMAHi 
myofibroblasts in tissue remodeling. These insights will help foster the rational design 
and clinical application of stromal cell-targeted therapies in cancer and fibrosis. 
Results 
Substratum directs activated fibroblast phenotypic heterogeneity.  
Primary murine adult pulmonary fibroblasts were cultured on tissue culture-
treated plastic for 2 passages, which generated a heterogeneous population of activated 
fibroblasts with variable levels of FAP and αSMA (data not shown). These fibroblasts 
were reseeded on plastic and the impact of soluble mediators thought to promote 
fibroblast activation5,6,115 on Fap and Acta2 gene expression was assessed. Consistent 
with prior studies10, treatment with a variety of fibrotic and inflammatory mediators (in 1% 
serum to minimize exogenous growth factors) modulated Acta2 expression. 
Unexpectedly, none of these mediators modulated Fap expression, except ascorbic 
acid, which promoted Fap expression at both the mRNA (Table 1 and Fig. 4A) and 
protein level (Fig. 4B).   
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Table 1. Fibroblasts cultured on plastic are resistant to induction of Fap 
expression.  
QRT-PCR analysis of Fap and Acta2 gene expression in fibroblasts (seeded in 1% 
serum on tissue culture-treated plastic) in response to 4-day treatment with indicated 
soluble mediators. The change in gene expression is indicated by the multiplier relative 
to the untreated control; NC denotes no change.  
 
Ascorbic acid (Vitamin C), an essential cofactor for lysyl and prolyl hydroxylation, 
promotes stable deposition of collagen (Fig. 4C) by ensuring proper folding of its triple 
helical structure116. Thus, we hypothesized that ascorbic acid regulates FAP expression 
by promoting ECM deposition. To test this hypothesis, fibroblasts were cultured on FN- 
and fibrillar collagen-rich fibroblast-derived matrices (FDMs; Fig. 4D). Interestingly, 
relative to culture on plastic, fibroblasts cultured on FDMs markedly up-regulated Fap 
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gene expression (Fig. 4E). Flow cytometric analysis further demonstrated that culture on 
FDMs versus plastic enriched for FAPHi fibroblasts (Fig. 4F). Moreover, a concomitant 
reduction in αSMAHi fibroblasts was observed on FDMs versus plastic (Fig. 4F). These 
data demonstrate that varying substrata can enrich for phenotypically distinct subsets of 
activated fibroblasts. 
 
Figure 4. Substratum directs activated fibroblast phenotypic heterogeneity.  
QRT-PCR (A) and representative flow cytometric analysis (B) of FAP and αSMA 
expression in fibroblasts cultured in 10% serum on tissue culture-treated plastic in the 
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presence or absence of 75 μg/ml ascorbic acid (Vit. C) for 4 days. Data were compiled 
from 4 independent experiments and bar graphs depict the mean +/- SEM. (C) Collagen 
levels (as measured via hydroxyproline content) in FDMs deposited by fibroblasts in the 
presence or absence of 75 μg/ml Vit. C. Data were compiled from 2 independent 
experiments and bar graphs depict the mean +/- SEM. (D) Representative IF staining of 
FN and two-photon second harmonic generation imaging of fibrillar collagen in lung 
FDMs. QRT-PCR (E) and representative flow cytometric analysis (F) of FAP and αSMA 
expression in fibroblasts in 10% serum on tissue culture-treated plastic or FDM for 4 
days. Data were compiled from 4 independent experiments and bar graphs depict the 
mean +/- SEM; ** p < 0.01. 
ECM composition and elasticity govern activated fibroblast phenotypic 
heterogeneity. 
Compared to plastic, FDMs constitute a more physiologically relevant substratum 
with respect to multiple parameters, including ECM compliance, architecture, and 
composition117. To delineate the roles of ECM elasticity and composition in driving 
activated fibroblast heterogeneity, we employed polyacrylamide hydrogels (where ECM 
ligand and elasticity can be independently controlled118). We primarily utilized 2 and 20 
kilopascal (kPa) hydrogels, which encompasses the range of stiffness found in 
pathophysiological conditions, including tumors and lung fibrosis110,111. Hydrogels were 
coated with FN or COL I to simulate early versus late stages, respectively, of wound 
repair, fibrosis, and tumorigenesis1–4.   
FN elasticity impacted fibroblast morphology, with reduced cell spreading and 
cytoskeletal organization after 72 hours of culture on 2 versus 20 kPa FN-coated 
hydrogels (Fig. 5A), consistent with previous reports119,120. Compared to 20 kPa FN-
coated hydrogels, 2 kPa FN-coated hydrogels promoted higher FAP and lower αSMA 
expression, at the mRNA (Fig. 5B) and protein (Fig. 5C) level. Across the 
pathophysiological stiffness range, Fap gene expression inversely correlated, while 
Acta2 gene expression directly correlated with FN stiffness (Fig. 5D, top panel). The full 
spectrum of activated fibroblast phenotypic differentiation (FAPHiαSMALow, FAPHiαSMAHi, 
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and FAPLowαSMAHi subsets) was observed on 2, 5, 12, and 20 kPa FN-coated hydrogels, 
as evidenced by flow cytometric analysis at the single cell level (Fig. 5D, bottom panel). 
However, our data clearly illustrate a shift in prevalence from the FAPHiαSMALow reactive 
fibroblast phenotype to the FAPLowαSMAHi myofibroblast phenotype with increasing FN 
stiffness (Fig. 5D, bottom panel).  
 
Figure 5. ECM composition and elasticity govern activated fibroblast phenotypic 
heterogeneity.  
Representative phalloidin staining of the actin cytoskeleton (A) and Fap and Acta2 gene 
expression (B) in fibroblasts cultured in 10% serum on 2 versus 20 kPa FN- or COL I-
coated hydrogels for 72 hours. Data were compiled from 4 independent experiments and 
20 
 
bar graphs depict the mean +/- SEM. (C) Representative flow cytometric analysis, 
including quantification of relative median fluorescent intensities (MFI) for FAP and 
αSMA expression in fibroblasts cultured in 10% serum on 2 kPa (blue) versus 20 kPa 
(red) FN-coated hydrogels for 72 hours. Data were compiled from 3 independent 
experiments and bar graphs depict the mean +/- SEM. (D) QRT-PCR (top) and flow 
cytometric analysis (bottom) of FAP and αSMA expression in fibroblasts cultured in 10% 
serum on 2, 5, 12, and 20 kPa FN-coated hydrogels for 72 hours. Data were compiled 
from 2 independent experiments and bar graphs depict the mean +/- SEM. (E) 
Representative flow cytometric analysis, including quantification of relative MFI for FAP 
and αSMA expression in lung fibroblasts cultured in 10% serum on 2 kPa (blue) versus 
20 kPa (red) COL I-coated hydrogels for 72 hours. Data were compiled from 3 
independent experiments and bar graphs depict the mean +/- SEM; * p < 0.05; ** p < 
0.01; *** p < 0.001; **** p < 0.0001. 
 
Unlike FN-coated hydrogels, both 2 and 20 kPa COL I-coated hydrogels 
promoted cell spreading and actin stress fiber formation after 72 hours of culture (Fig. 
5A). Moreover, both 2 and 20 kPa COL I-coated hydrogels promoted low Fap and high 
Acta2 gene expression (Fig. 5B), thereby enriching for FAPLowαSMAHi myofibroblasts 
(Fig. 5E). Taken together, these data indicate that an integrated response to ECM 
composition and elasticity governs activated fibroblast heterogeneity.  
Fibroblast differentiation in response to transforming growth factor beta (TGF-β) 
is governed by ECM composition and elasticity. 
To dissect the role of growth factors in regulating fibroblast heterogeneity, 
fibroblasts were cultured in low (1%) serum (to minimize exogenous growth factors) on 
FN- or COL I-coated hydrogels (2 or 20 kPa) for 72 hours. ECM stiffness regulated 
Acta2 expression, even in 1% serum (Fig. 6A). In contrast, Fap expression was 
comparably low in fibroblasts on all substrata in 1% serum (Fig. 6A), unlike in 10% 
serum (Fig. 5). Serum contains appreciable levels of TGF-β, a pro-fibrotic cytokine 
thought to promote fibroblast activation. Therefore, we investigated the role of TGF-β-
mediated signaling in ECM-dependent regulation of FAP expression by using both gain- 
and loss-of-function approaches. Addition of recombinant, active TGF-β to 1% serum 
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was sufficient to promote the FAPHiαSMALow reactive fibroblast phenotype on 2 kPa FN-
coated hydrogels. Conversely, TGF-β promoted the FAPLowαSMAHi myofibroblast 
phenotype on 2 kPa COL I-coated hydrogels and 20 kPa hydrogels coated with either 
FN or COL I (Fig. 6A-B).  
To determine whether TGF-β was necessary for the response to serum, 
fibroblasts in 10% serum were treated with calcipotriol, a vitamin D receptor (VDR) 
agonist that inhibits TGF-β/SMAD signaling via genomic competition87. The expression 
of Cyp24a1, a VDR target gene, was measured as a positive control for calcipotriol 
efficacy. Interestingly, calcipotriol induced higher Cyp24a1 expression in fibroblasts 
cultured on 2 versus 20 kPa FN-coated hydrogels (Fig. 6C), indicating that high ECM 
stiffness can confer resistance to calcipotriol. Furthermore, calcipotriol attenuated high 
Fap and Acta2 gene expression in fibroblasts on 2 and 20 kPa FN-coated hydrogels, 
respectively (Fig. 6C). These findings demonstrate that VDR agonists can curtail both 
activated fibroblast phenotypes.  
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Figure 6. Fibroblast differentiation in response to TGF-β is governed by ECM 
composition and elasticity.  
QRT-PCR (A) and flow cytometric analysis (B) of FAP and αSMA expression in 
fibroblasts that were seeded in 1% serum on 2 versus 20 kPa COL I- or FN-coated 
hydrogels, allowed to adhere overnight, and subsequently treated with 2 ng/ml TGF-β for 
48 (A) or 72 hours (B). Data were compiled from 4 independent experiments and bar 
graphs depict the mean +/- SEM. (C) QRT-PCR analysis of Fap, Acta2, and Cyp24a1 
gene expression in fibroblasts that were seeded in 10% serum on FN-coated hydrogels 
(2 or 20 kPa), allowed to adhere overnight, and subsequently treated with calcipotriol 
(Cal; 100 or 500 nM) or vehicle control (-) for 48 hours. Data were compiled from 3 
independent experiments and bar graphs depict the mean +/- SEM; * p < 0.05; ** p < 
0.01; *** p < 0.001; **** p < 0.0001. 
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Neither ROCK nor FAK activity are required to induce the FAPHi reactive fibroblast 
phenotype.  
Both Rho kinase (ROCK) and focal adhesion kinase (FAK) activity can promote 
αSMAHi myofibroblast differentiation. ROCK activity facilitates the actin cytoskeletal 
reorganization necessary for myofibroblast differentiation in response to ECM 
stiffening121. FAK activity facilitates TGF-β-induced myofibroblast differentiation122. 
Furthermore, FN-mediated FAK activation depends on stiffness, since exposure of the 
cryptic FN synergy site requires mechanical tension123. Therefore, we assessed whether 
ROCK or FAK activity similarly regulate FAPHi reactive fibroblast differentiation. FAPHi 
fibroblasts (on 2 kPa FN) and αSMAHi myofibroblasts (on 20 kPa FN) were treated with a 
ROCK (Y-27632) or FAK (PF573228) inhibitor. As expected, ROCK inhibition attenuated 
actin stress fiber formation (Fig. 7A) and Acta2 expression (Fig. 7B) on 20 kPa FN-
coated hydrogels. In contrast, ROCK inhibition had no effect on Fap expression on 2 or 
20 kPa FN-coated hydrogels (Fig. 7B). Treatment with PF573228 diminished FAK 
activity, as indicated by reduced phospo-FAKTyr397 levels (Fig. 7C). However, FAK 
inhibition did not revert either the FAPHi or αSMAHi phenotype on 2 or 20 kPa FN, 
respectively (Fig. 7D). Thus, FAK activity does not appear to be required for the 
induction of either activated fibroblast phenotype in response to changes in FN elasticity.   
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Figure 7.  Neither ROCK nor FAK activity are required to induce the FAPHi reactive 
fibroblast phenotype.  
Phalloidin staining of the actin cytoskeleton (A) and qRT-PCR analysis of Fap and Acta2 
gene expression (B) in fibroblasts seeded in 10% serum on 2 versus 20 kPa FN-coated 
hydrogels, allowed to adhere overnight, and subsequently treated with 10 μM Y-27632 
or vehicle control (-) for 48 hours. Data were compiled from 3 independent experiments 
and bar graphs depict the mean +/- SEM; ** p < 0.01. Immunoblot for p-FAKTyr397 and 
total FAK protein levels (C) and quantification (D; representative of 2 independent 
experiments) of qRT-PCR analysis of Fap and Acta2 gene expression in fibroblasts that 
were seeded (and subsequently cultured for 72 hours) in 10% serum supplemented with 
PF-573228 (1 or 5 μM) or vehicle control (-).     
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Gene expression profiling indicates that FAPHi reactive fibroblasts predominantly 
synthesize and proteolyze ECM, while αSMAHi myofibroblasts mediate contraction. 
To identify potentially unique functional roles of fibroblast subsets in tissue 
remodeling, we compared gene expression profiles of fibroblasts cultured in 10% serum 
on 2 (enriched for FAPHi reactive fibroblasts) versus 20 (enriched for αSMAHi 
myofibroblasts) kPa FN-coated hydrogels. FAPHi fibroblasts exhibited a more ECM 
proteolytic phenotype, with higher gene expression of most matrix metalloproteinases 
(Mmps) and tissue plasminogen activator (Plat; Fig. 8A). Meanwhile, gene expression of 
most tissue inhibitors of metalloproteinases (Timps) was comparable or reduced in 
FAPHi compared to αSMAHi fibroblasts (Fig. 8A). FAPHi fibroblasts also exhibited higher 
gene expression of many ECM and matricellular constituents, including collagens I 
(Col1a1) and III (Col3a1), decorin (Dcn), extra domain A FN (EDA-Fn1), thrombospondin 
2 (Thbs2), and osteopontin (Spp1; Fig. 8A-B). Collectively, these results implicate FAPHi 
fibroblasts in the dynamic ECM deposition and turnover characteristic of desmoplastic 
tissue.  
On the other hand, FAPHi fibroblasts showed lower gene expression of 
constituents of the actomyosin contractile apparatus, such as smooth muscle myosin 
heavy chain (Myh11; Fig. 8B) and beta actin (Actb; Fig. 8C). Furthermore, the gene 
expression of mediators known to promote fibroblast contractility, including caveolin-1 
(Cav1) and endothelin (Edn1), was attenuated in FAPHi compared to αSMAHi fibroblasts 
(Fig. 8C). The reduced gene expression of most integrin subunits in FAPHi fibroblasts 
(Fig. 8C) also indicates reduced contractile capacity, considering the necessity of 
integrins for fibroblasts to exert contractile force on ECM112. The gene expression of lysyl 
oxidase (Lox), an enzyme that crosslinks collagen, was also reduced in FAPHi fibroblasts 
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(Fig. 8C). Taken together, these results suggest that FAPHi reactive fibroblasts have a 
diminished capacity to contract, crosslink, and, consequently, stiffen ECM compared to 
αSMAHi myofibroblasts.  
FAPHi reactive fibroblasts and αSMAHi myofibroblasts also diverged with respect 
to their gene expression of growth factors, inflammatory mediators, and regulators of cell 
cycle progression. Compared to αSMAHi myofibroblasts, FAPHi fibroblasts expressed 
lower mRNA levels of autocrine growth factors that can promote myofibroblast 
differentiation and expansion, including connective tissue growth factor (Ctgf), platelet 
derived growth factor α (Pdgfa), Tgfb2, and Tgfb3 (Fig. 8D). Conversely, FAPHi 
fibroblasts expressed higher mRNA levels of hepatocyte growth factor (Hgf), a paracrine 
growth factor known to promote epithelial proliferation and survival (Fig. 8D). FAPHi 
fibroblasts also expressed higher mRNA levels of most inflammatory mediators 
assessed in our fibrosis array, however, they were expressed at low levels, exhibited 
relatively high variability, and did not achieve statistical significance at a confidence level 
of 95% (Table 2). Lastly, FAPHi fibroblasts exhibited lower gene expression of pro-
proliferative transcription factors, such as jun oncogene (Jun; Fig. 8D) and 
myelocytomatosis oncogene (Myc; Fig. 8D), and mediators of cell cycle progression, 
such as cyclin A2 (Ccna2; Fig. 8B), suggestive of a less proliferative phenotype.   
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Figure 8. Gene expression profiling indicates that FAPHi reactive fibroblasts 
predominantly synthesize and proteolyze ECM, while αSMAHi myofibroblasts 
mediate contraction.  
Comparison of gene expression profiles, assessed via Qiagen Fibrosis Gene Expression 
Array (A, C, and D) and independent qRT-PCR analyses (B), of fibroblasts cultured in 
10% serum on 2 (FAPHi fibroblasts) or 20 kPa (αSMAHi fibroblasts) FN-coated hydrogels 
for 72 hours. Relative gene expression (FAPHi/αSMAHi fibroblasts) of ECM proteases (A), 
ECM protease inhibitors (A), ECM and matricellular components (A and B), contractile 
mediators (B and C), integrin subunits (C), growth factors (D), and proliferative 
mediators (B and D). Data were compiled from 3 independent experiments and bar 
graphs depict the mean +/- SEM; * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Table 2 (Part 1). Raw data from the Qiagen RT² Profiler Mouse Fibrosis PCR Array.  
Gene expression values (normalized to β2 microglobulin mRNA levels) in fibroblasts 
cultured in 10% serum on 2 or 20 kPa FN-coated hydrogels for 72 hours. ND denotes no 
detectable signal.  
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Table 2 (Part 2). Raw data from the Qiagen RT² Profiler Mouse Fibrosis PCR Array.  
Gene expression values (normalized to β2 microglobulin mRNA levels) in fibroblasts 
cultured in 10% serum on 2 or 20 kPa FN-coated hydrogels for 72 hours. ND denotes no 
detectable signal.  
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Discussion 
In summary, we delineated features of remodeling tissues that direct activated 
fibroblast heterogeneity. In our proposed model (Fig. 9), a convergence of ECM 
composition, elasticity, and TGF-β signaling governs FAPHiαSMALow, FAPHiαSMAHi, and 
FAPLowαSMAHi fibroblast phenotypic heterogeneity. These data help explain the 
activated fibroblast heterogeneity observed in vivo, where FAP and αSMA identify 
distinct, yet overlapping, fibroblast subsets. This heterogeneity likely stems from the 
spatiotemporally dynamic variation in ECM composition and elasticity in injury, fibrosis, 
and cancer1,108–113. Furthermore, our gene expression profiling data indicate potentially 
unique functionality of these fibroblast subsets in tissue remodeling. FAPHi reactive 
fibroblasts exhibited an ECM synthetic and proteolytic phenotype, while αSMAHi 
myofibroblasts exhibited a contractile and proliferative phenotype.  
 
Figure 9. A convergence of ECM composition, elasticity, and TGF-β signaling 
governs activated fibroblast phenotypic heterogeneity.  
In FN-rich ECMs of low stiffness, TGF-β promotes the FAPHiαSMALow reactive fibroblast 
phenotype. Conversely, TGF-β promotes the FAPLowαSMAHi myofibroblast phenotype in 
the context of stiff and/or COL I-rich ECMs. Gene expression profiling indicates unique 
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functionality of these divergent fibroblast subsets in tissue remodeling, with FAPHi 
reactive fibroblasts exhibiting an ECM synthetic and proteolytic phenotype, and αSMAHi 
myofibroblasts exhibiting a contractile and proliferative phenotype.   
 
Extrapolating our model to the well-characterized progression of acute injury 
resolution109 illuminates ECM-dependent regulation and diverse functionality of fibroblast 
subsets in tissue remodeling. In early wounds, the highly elastic, FN-rich environment 
likely promotes FAPHi fibroblast differentiation. The gene expression profile of FAPHi 
fibroblasts suggests that they orchestrate early phases of wound resolution by secreting: 
(1) ECM proteases to facilitate cell migration into the wound, (2) paracrine growth factors 
to support re-epithelialization, and (3) ECM and matricellular components to replace 
provisional ECM with COL 1-rich connective tissue. Thereafter, the stiff, COL 1-rich 
environment of late granulation tissue likely promotes αSMAHi myofibroblast 
differentiation. The gene expression profile of αSMAHi myofibroblasts suggests that they 
orchestrate late phases of wound resolution, including fibro-proliferation (via secretion of 
autocrine growth factors) and wound closure (via contraction). We are now conducting 
studies utilizing murine models of tissue injury to assess this proposed model of 
temporal regulation and diverse functionality of FAPHi and αSMAHi fibroblasts in wound 
resolution.     
Comparable regulation and functionality of FAPHi and αSMAHi fibroblast subsets 
likely occur in tumors, considering the parallels between the wound healing response 
and tumorigenesis1–3. Previous studies have characterized diverse mechanisms by 
which carcinoma-associated fibroblasts promote tumor growth. However, the diverse 
roles of fibroblast subsets in tumorigenesis remained unclear. Our gene expression 
analysis suggests that FAPHi and αSMAHi fibroblasts diverge in their tumor-promoting 
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functions. For example, αSMAHi myofibroblasts express higher mRNA levels of Lox, an 
enzyme that stiffens ECM by crosslinking collagen, which promotes focal adhesions, 
PI3K signaling, and consequently, tumor invasion72. αSMAHi myofibroblasts also exhibit 
higher gene expression of Cav1, which promotes Rho-dependent contraction, ECM 
alignment and stiffening, and consequently, tumor invasion124. Meanwhile, FAPHi 
fibroblasts exhibit higher gene expression of many tumor-promoting ECM proteases, 
including Fap itself and most Mmps. Extensive research has previously demonstrated 
fundamental roles of these stromal proteases in tumor invasion125, angiogenesis25,126, 
proliferation25,127,128, and epithelial-mesenchymal transition129,130. Moreover, compared to 
αSMAHi myofibroblasts, FAPHi fibroblasts exhibit higher gene expression of Hgf, a 
previously described mechanism by which stromal fibroblasts promote oncogenesis and 
resistance to targeted cancer therapies131,132.  
Importantly, our study addresses the ongoing controversy regarding intratumoral 
fibroblasts as therapeutic targets133,134. A number of  laboratories have employed diverse 
approaches to deplete FAPHi fibroblasts in murine tumor models16,95–100,104. Virtually all 
these studies illustrated that depletion of FAPHi fibroblasts disrupts desmoplastic stroma 
and impedes tumor progression, corroborating the data presented herein and the 
correlation between high FAP expression and poor prognosis in myriad solid tumor 
types29–45. On the contrary, the net effect of αSMAHi myofibroblasts in tumor progression 
remains obfuscated due to conflicting reports. Although many studies have 
demonstrated a pro-tumorigenic role for αSMAHi myofibroblasts135,136, one recent study 
utilizing αSMA-thymidine kinase (tk) transgenic mice demonstrated that depletion of 
proliferating αSMAHi myofibroblasts (via systemic ganciclovir administration) accelerated 
pancreatic ductal adenocarcinoma aggressiveness56. Importantly, αSMAHi myofibroblast 
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depletion did not diminish the prevalence of FAPHi fibroblasts56, a population that 
possesses unique tumor-promoting capabilities. In contrast, FAPHi fibroblast depletion 
also eliminated most intratumoral αSMAHi myofibroblasts16. Thus, FAPHi fibroblast 
depletion may have demonstrated superior anti-tumor efficacy than αSMAHi 
myofibroblast depletion because it eliminated heterogeneous, tumor-promoting 
populations of activated fibroblasts. Alternately, the net benefit of FAPHi fibroblast 
depletion may have overcome the potential detrimental effect of αSMAHi myofibroblast 
depletion. The heterogeneity of the input population for our experiments suggests that 
either: (1) varying substrata supports the survival and/or growth of divergent fibroblast 
subsets, or (2) activated fibroblasts possess plasticity enabling them to adopt the 
FAPHiαSMALow, FAPHiαSMAHi, or FAPLowαSMAHi phenotype, depending on substratum. 
Future studies should investigate the lineage, interdependence, and plasticity of these 
activated fibroblast subsets in vivo. FAPHi fibroblasts may facilitate the generation and/or 
recruitment of αSMAHi myofibroblasts, or myofibroblast precursors may express FAP.  
Unraveling the complex regulation of fibroblast heterogeneity will hasten the 
successful application of therapies that target fibroblasts. In fact, our findings may help 
explain recent failures in clinical trials of a few molecularly targeted approaches. For 
example, simtuzumab (an antibody that blocks LOXL2 enzymatic activity) failed in 
clinical trials for colorectal adenocarcinoma137, metastatic pancreatic adenocarcinoma138, 
and idiopathic pulmonary fibrosis139,140. The clinical use of simtuzumab aimed to curb 
tumor and fibrosis progression by reducing ECM stiffness and myofibroblast generation. 
Our finding that FAPHi fibroblasts prevail at low stiffness might help explain the inefficacy 
of simtuzumab, considering the tumor- and fibrosis-promoting propensities of FAPHi 
fibroblasts. The attenuation of myofibroblast generation via inhibitors of sonic hedgehog 
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signaling may have failed in clinical trials for similar reasons91,93,94. Intriguingly, 
calcipotriol-mediated blockade of TGF-β/SMAD signaling (currently being evaluated in 
clinical trials) has shown promise in pre-clinical models of both pancreatic ductal 
adenocarcinoma and liver cirrhosis87,88. We have now demonstrated that calcipotriol can 
attenuate fibroblast activation to both the FAPHi and αSMAHi phenotype, which helps 
explain the efficacy of calcipotriol in treating both fibrosis and cancer. Overall, our 
findings underscore the importance of comprehensive monitoring of heterogenous 
fibroblast populations in response to stroma-targeted therapies to identify optimal 
treatment modalities.   
Future Directions 
 Importantly, these data are the first (to our knowledge) to disentangle the 
regulation and potentially unique functionality of heterogeneous activated fibroblast 
subsets. Future research should build on these results to more precisely delineate the 
unique roles of activated fibroblast subsets.  
Although our work illustrated key roles of FN, COL 1, and TGF-β in regulating 
activated fibroblast phenotypic heterogeneity, other soluble factors and ECM 
components present in actively remodeling tissue likely participate in this phenotypic 
regulation. Fibroblasts cultured on plastic were resistant to induction of Fap expression 
in response to treatment with various soluble mediators thought to promote fibroblast 
activation. However, a screen should be performed on 2 and 20 kPa FN-coated 
hydrogels to determine whether these soluble factors regulate Fap expression under 
more physiologically relevant conditions (as observed with TGF-β). Furthermore, our 
studies only utilized hydrogels coated with FN or COL 1 to simulate early versus late 
stages, respectively, of wound repair, fibrosis, and tumorigenesis1–4. Follow-up studies 
35 
 
should assess activated fibroblast heterogeneity on 2 and 20 kPa hydrogels coated with 
other prevalent ECM components in tumors, fibrosis, and granulation tissue, such as 
fibrin, EDA-FN, and collagen III (COL 3). Unlike COL 1, COL 3 expression peaks at early 
stages of wound repair108,141,142. Furthermore, COL 3-deficient excisional wounds 
contract at accelerated rates and COL 3-deficient fibroblasts display increased 
myofibroblast differentiation142. Thus, considering its role in restraining myofibroblast 
differentiation, COL 3 (unlike COL 1) likely promotes the FAPHiαSMALow phenotype at 2 
kPa. If true, this result could explain how fibrillar collagen-rich FDMs promote the FAPHi 
phenotype. Considering the higher gene expression of Col3a1 versus Col1a1 in FAPHi 
fibroblasts (Table 2), COL3 likely constitutes the majority of fibrillar collagen 
accumulating in FDMs. Therefore, further analysis (IF or immunoblot) should 
characterize the fibrillar collagen in FDMs.  
Future studies should also further elucidate the signaling pathways driving this 
phenotypic heterogeneity. Notably, cell toxicity was observed at the doses of PF573228 
(> 10 μM) required to fully abrogate FAK activity. To definitively rule out FAK activity in 
the regulation of either activated fibroblast phenotype, future experiments should utilize 
adenoviruses encoding FAK mutants, including FRNK (a dominant-negative, FAK-
related nonkinase), FAK397F (a non-phosphorylatable FAK mutant), and CD2-FAK (a 
constitutively active FAK). Moreover, although our studies illustrated that TGF-β is 
sufficient to promote the FAPHi fibroblast phenotype, further validation is warranted to 
determine whether TGF-β signaling is necessary for this phenotype. Thus, our results 
with calcipotriol (which does not exclusively target TGF-β/SMAD signaling) need to be 
corroborated using either TGF-β type II receptor antagonists or TGF-β neutralizing 
antibodies.   
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 Lastly, follow-up experiments should compare the unique functionality of 
heterogeneous activated fibroblasts. Some of the differences between FAPHi (on 2 kPa 
FN) and αSMAHi fibroblasts (on 20 kPa FN) identified in my gene expression array may 
solely be stiffness-dependent, rather than consistent differences between FAPHi and 
αSMAHi fibroblasts (regardless of context).  Therefore, expression of key genes identified 
in my array (such as Col1a1, Col3a1, Spp1, Mmps, Hgf, Ctgf, and Edn1) should be 
compared on 2 kPa FN (FAPHi), 20 kPa FN (αSMAHi), 2 kPa COL 1 (αSMAHi), and 20 
kPa COL 1 (αSMAHi). Furthermore, the unique functionality of FAPHi and αSMAHi 
fibroblasts should be assessed by comparing their contractility (using atomic force 
microscopy), proliferation, collagenase and/or gelatinase activity (using DQ gelatin or 
collagen), and secretion of growth factors, ECM components, and inflammatory 
cytokines. Taken together, these experiments would elucidate how the functional roles of 
activated fibroblasts evolve in response to changes in ECM composition and stiffness in 
actively remodeling tissues.   
Methods 
Isolation of murine lung fibroblasts 
Lungs were harvested from 10- to 16-week-old male or female C57BL/6 (Charles 
River) mice. Lungs were finely minced, then digested in a cocktail of collagenases I, II, 
and IV (Worthington; each at 250 μg/ml in DMEM) at 37°C for 2 hours. The collagenase 
solution was quenched with an equivalent volume of 10% heat-inactivated fetal calf 
serum (FCS) DMEM. The digested tissue was sequentially strained through 70 and 40 
μm cell strainers then spun at 1200 r.p.m. for 10 minutes at 4°C. The cell pellet was re-
suspended in 10% FCS DMEM (containing HEPES, L-glutamine, penicillin-streptomycin, 
fungizone, and gentamicin) and plated on tissue culture-treated plastic (polystyrene). 
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Cells were maintained at 37°C with 5% CO2 in a humidified incubator. The next day, cell 
monolayers were washed several times with PBS to remove non-adherent cells. Cells 
were maintained in 10% FCS DMEM on tissue culture-treated plastic for two passages. 
Second passage fibroblasts were used for all experiments. 
Fibroblast-derived matrices (FDMs) 
Decellularized FDMs were generated as described previously143, using murine 
lung fibroblasts cultured at confluence in the presence of 75 μg/ml ascorbic acid for 8 
days.    
Hydrogels 
Polyacrylamide hydrogels of varying stiffness were prepared and coated 
overnight at 4°C with bovine FN (EMD Millipore; 5 μg/ml) or COL I (PureCol; Advanced 
BioMatrix; 10 μg/ml) as described previously118. Hydrogels were rinsed twice with PBS 
and unreacted N-hydroxysuccinimide was blocked with 1 mg/ml heat-inactivated bovine 
serum albumin in serum-free DMEM for 30 minutes at 37°C. Hydrogels were rinsed 
twice with PBS before cell seeding.  
RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) 
 Cells were rinsed with PBS, lysed in 1 ml Trizol (Invitrogen), and processed for 
RNA extraction according to manufacturer’s instructions. After quality assessment by 
agarose gel electrophoresis, reverse transcription was performed following the standard 
protocol for the TaqMan Reverse Transcription kit (Applied Biosystems). Transcript 
levels were assayed via the StepOnePlus Real-Time PCR System (Applied Biosystems) 
using SYBR Green (Invitrogen). mRNA levels for all genes of interest were normalized to 
Hprt1 mRNA levels. Primer sequences: Fap-F, 5’-cacctgatcggcaatttgtg; Fap-R, 5’-
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cccattctgaaggtcgtagatgt; Acta2-F, 5’-ccagagcaagagagggatcct; Acta2-R, 5’-
tgtcgtcccagttggtgatg; Hprt1-F, 5’-tgacactggtaaaacaatgca; Hprt1-R, 5’-
ggtccttttcaccagcaagct; Tnc-F, 5’-ggacttacgggtgtctgaaacc; Tnc-R, 5’-
tgaggcggtaacgatcaaact; Cyp24a1-F, 5’-ccagcggctagagatcaaac; Cyp24a1-R, 5’-
cacgggcttcatgagtttct; Spp1-F, 5’-ccctcgatgtcatccctgtt; Spp1-R, 5’-tgccctttccgttgttgtc; 
Myh11-F, 5’-gacaactcctctcgctttgg; Myh11-R, 5’-gctctccaaaagcaggtcac; Ccna2-F, 5’-
tggatggcagttttgaatcacc; Ccna2-R, 5’-ccctaaggtacgtgtgaatgtc; EDA-Fn1-F, 5’-
cgagccctgaggatggaat; EDA-Fn1-R, 5’-agctctgcagtgtcgtcttcac; Has2-F, 5’-
cggtcgtctcaaattcatctg; Has2-R, 5’-acaatgcatcttgttcagctc. 
Fibrosis gene expression array 
RNA was extracted as described above. RNA purification was performed 
following the standard protocol for the RNeasy Mini Kit with on-column DNase digestion 
(Qiagen). After quality assessment by agarose gel electrophoresis, cDNA was 
synthesized (using 1 µg RNA per sample) with the RT2 First Strand Kit (Qiagen). Both 
RNA and cDNA quality were confirmed using the Murine RT² Profiler Quality Control 
Array (Qiagen). Transcript levels were assessed with the RT² Profiler Mouse Fibrosis 
PCR Array (Qiagen) using RT2 Sybr Green ROX qPCR Mastermix (Qiagen). RNA levels 
for all genes of interest were normalized to β2 microglobulin (β2M) mRNA levels.   
Flow cytometry 
For hydrogel (Figs. 5-6) and Vit. C (Fig 4B) experiments, cells were trypsinized to 
obtain a single cell suspension. For FDM experiments (Fig. 4F), cells (on plastic or FDM) 
were trypsinized, and then incubated with 500 μg/ml collagenase I (Worthington) for 30 
minutes at 37°C to obtain a single cell suspension. Flow cytometric analyses were 
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performed on an LSR-Fortessa using FACSDiva software (BD Bioscience) and data 
were analyzed using FlowJo (Tree Star). 
Antibodies used for flow cytometry 
Biotinylated anti-FAP (Clone 73-3) antibody was generated in-house, and 
detected using Streptavidin-APC (BioLegend). The specificity of the anti-FAP antibody 
was verified based on reactivity with cells from wild-type but not FAP-null mice. Dead 
cells were excluded by using the Live/Dead Fixable Violet Dead Cell Stain Kit (Molecular 
Probes). Staining with anti-αSMA antibody (Sigma, clone1A4, FITC) was performed after 
permeabilizing cell suspensions with the Cytofix/Cytoperm Fixation/Permeabilization Kit 
(BD Biosciences), as per the manufacturer’s instructions.  
Treatment with inhibitors or soluble factors 
For indicated experiments, cells were treated with recombinant human active 
TGF-β (R&D), PF573228 (Tocris), Y-27632 (Sigma), calcipotriol (Tocris), L-ascorbic acid 
(Vit. C; Fisher), basic fibroblast growth factor (bFGF; Peprotech), interleukin (IL)-1β 
(Peprotech), IL-3 (Peprotech), interferon gamma (IFNγ; R&D), IL-6 (Peprotech), tumor 
necrosis factor alpha (TNFα; Peprotech), high molecular weight hyaluronan (HMW HA; 
Healon), low molecular weight hyaluronan (LMW HA; ICN Biochemicals), periostin/OSF-
2 (R&D), buthionine-sulfoximine (BSO; Sigma), tiron (Sigma), trichostatin A (Sigma), 
pleiotrophin (R&D), angiotensin II (Sigma), and platelet-derived growth factor-bb 
(PDGFbb; Calbiochem). 
Immunoblot 
Total cell lysates were prepared from fibroblasts cultured on hydrogels by placing 
coverslips face down on 4X NuPAGE LDS Sample Buffer (Invitrogen; supplemented with 
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10 mM 2-mercaptoethanol) for 2 minutes. Cell lysates were then heated at 70°C for 10 
minutes. Equal amounts of extracted protein were resolved on NuPAGE 4-12% Bis-Tris 
gels (Invitrogen) and the fractioned proteins were transferred onto PVDF membranes. 
Membranes were probed with antibodies to FAK (Cell Signaling, 3285) and phospo-
FAKTyr397 (Cell Signaling, 3283), followed by HRP-conjugated goat anti-rabbit secondary 
antibody (Sigma, A0545).  
Microscopy 
Imaging of fibrillar collagen in decellularized fibroblast-derived matrices was 
based on second harmonic generation utilizing a Leica SP5 confocal/multiphoton 
microscope (Leica Microsystems) at 20X magnification, as described previously144. 
Immunofluorescent (IF) images were obtained with a Nikon Eclipse Ti-E inverted 
microscope at 10X (FN) or 20X (phalloidin) magnification.  
Hydroxyproline assay  
Collagen content in FDMs produced by lung fibroblasts (in the presence or 
absence of 75 μg/ml ascorbic acid) was quantified by measuring hydroxyproline levels 
(normalized to cell number as measured by calcein AM levels), as previously 
described145. 
IF 
For FN IF, FDMs produced by lung fibroblasts were incubated with rabbit anti-FN 
antibody (Sigma, Clone F3648), followed by Alexa Fluor 658 goat anti-rabbit antibody 
(Invitrogen). For visualization of the actin cytoskeleton, lung fibroblasts on 2 and 20 kPa 
hydrogels were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-X-100, 
then stained with Alexa Fluor 594-conjugated phalloidin (Molecular Probes) and DAPI.  
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Statistics 
All results are reported as mean (of the indicated number of independent 
experiments) +/- standard error of the mean (SEM). Statistical analysis was performed 
using one-way analysis of variance (ANOVA) with the Tukey’s multiple comparison test 
or two-tailed Student’s t test (Prism 7.0, GraphPad Software). Asterisks denote statistical 
significance: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. 
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CHAPTER THREE: THE ROLE OF FAP-DEPENDENT ECM REMODELING IN LUNG 
TUMORIGENESIS   
Introduction  
The desmoplastic reaction, a complex process involving the recruitment and 
differentiation of CAFs together with extensive ECM remodeling, plays a crucial role in 
tumor development6,64,112,146. However, the mechanisms by which desmoplasia regulates 
tumor development remain mostly undefined. Delineating these mechanisms will enable 
the refinement of integrative cancer therapy, whereby neoplastic and stromal cells are 
simultaneously targeted, potentially resulting in synergistic anti-tumor efficacy. 
In virtually all carcinomas, a subset of CAFs express FAP, a cell surface serine 
protease with both endopeptidase and dipeptidyl peptidase activity18,20,22. The selective 
expression of FAP in the tumor microenvironment makes it an attractive drug target15–19. 
Our laboratory previously demonstrated that both Fap genetic deletion and 
pharmacological inhibition of FAP enzymatic activity attenuate tumor burden and 
proliferation in an inducible, autochthonous lung tumor model (the Lox-Stop-Lox (LSL) 
KrasG12D/+ model). However, the LSL-KrasG12D/+ model has notable drawbacks. The 
tumors in this model exhibit only modest intratumoral desmoplasia, making it difficult to 
study ECM remodeling. Furthermore, the necessary viral administration for tumor 
initiation induces an inflammatory response, which can influence tumorigenesis. 
Therefore, in this study, we extended our analyses by comparing lung tumor 
development and intratumoral desmoplasia in two additional models, the LSL-
KrasG12D/+;Tgfbr2flox/flox model model and the KrasG12D latent allele 2 (KrasLA2/+) model. 
Highly desmoplastic lung tumors develop in the LSL-KrasG12D/+;Tgfbr2flox/flox model, 
making it an attractive model to study intratumoral ECM remodeling. Meanwhile, the 
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spontaneous nature of tumor initiation in the KrasLA2/+ model avoids the potentially 
confounding influence of viral administration.  
The diminished lung tumor burden in FAP-deficient LSL-KrasG12D/+ mice was 
associated with excess collagen accumulation and dysregulated integrin-mediated 
signaling25. Recent studies also demonstrated that FAP cleaves MMP-1-digested 
collagen I and III, and that FAP-mediated collagen proteolysis promotes cellular uptake 
and turnover of collagen23,24. Therefore, considering the importance of desmoplasia in 
tumorigenesis, we hypothesized that FAP-dependent collagen proteolysis and ECM 
remodeling directly promote tumor cell proliferation and invasion. To test this hypothesis, 
we employed FDMs as a reductionist approach to assess the direct effect of FAP-
dependent ECM remodeling on tumor cell proliferation and migration.  
We demonstrated that Fap genetic deletion promotes intratumoral fibrillar 
collagen accumulation and attenuates lung tumor multiplicity, size, progression, and 
proliferation in the KrasLA2/+ model. Furthermore, we obtained preliminary evidence that 
Fap-/- lung fibroblasts produce ECM with enhanced fibrillar collagen accumulation, which 
directly impedes both tumor cell proliferation and motility. These studies validate FAP as 
a drug target in the treatment of lung cancer and help explain how FAP promotes lung 
tumor growth, further clarifying the mechanisms by which desmoplasia regulates 
tumorigenesis. 
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Results 
Fap+/+, Fap+/-, and Fap-/- mice exhibit equivalent lung tumor burden in the LSL-
KrasG12D/+;Tgfbr2flox/flox model of lung adenocarcinoma. 
We sought to investigate the role of FAP-dependent ECM remodeling in 
tumorigenesis by utilizing a highly desmoplastic lung tumor model. For this purpose, we 
employed the LSL-KrasG12D/+Tgfbr2flox/flox model, characterized by highly invasive tumors 
with abundant desmoplasia147 (Fig. 10A). In this model, lung tumorigenesis is initiated by 
intranasal administration of adenovirus expressing cre recombinase (Ad-cre), which 
causes activation of oncogenic Kras (KrasG12D) and loss of TGF-β type II receptor in 
targeted cells. Surprisingly, however, LSL-KrasG12D/+;Tgfbr2flox/flox;Fap+/+, LSL-
KrasG12D/+;Tgfbr2flox/flox;Fap+/-, and LSL-KrasG12D/+;Tgfbr2flox/flox;Fap-/- mice exhibited nearly 
equivalent lung tumor burden (Fig. 10B-C), distinguishing it from other lung, breast, and 
pancreatic autochthonous tumor models that we have assessed in our lab to date. 
Therefore, we deemed the LSL-KrasG12D/+TGFBR2flox/flox lung cancer model an unsuitable 
model to delineate the mechanisms by which FAP-mediated ECM remodeling promotes 
tumorigenesis.   
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Figure 10. Fap+/+, Fap+/-, and Fap-/- mice exhibit equivalent lung tumor burden in the 
LSL-KrasG12D/+;Tgfbr2flox/flox model of lung adenocarcinoma. 
Representative Dichrome staining (A), H&E staining (B), and quantification of tumor 
burden (C) in LSL-KrasG12D/+;Tgfbr2flox/flox;Fap+/+ (n=14 mice), LSL-
KrasG12D/+;Tgfbr2flox/flox;Fap+/- (n=5 mice), and LSL-KrasG12D/+;Tgfbr2flox/flox;Fap-/- (n=9 mice) 
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lung tissue sections (8 weeks after initiating tumorigenesis via intranasal administration 
of Ad-cre). Bar graph depicts the mean +/- SEM.  
 
Fap genetic deletion restrains lung tumor progression and growth in the 
spontaneous KrasLA2/+ model of lung tumorigenesis.  
The inducible LSL-KrasG12D/+ model has notable caveats, including the 
promiscuous targeting of varied cell types in the lung by intranasal administration. 
Furthermore, the inflammatory response induced by Ad-cre administration likely exerts a 
profound and confounding influence on tumor development. Therefore, we investigated 
the role of FAP in tumorigenesis in the spontaneous KrasLA2/+ lung tumor model148. In this 
model, mice harbor latent, oncogenic KrasG12D that spontaneously activates in vivo via 
genetic recombination. KrasLA2/+ mice develop lung tumors with 100% penetrance that 
evolve from hyperplasia to adenoma (or carcinoma, in some cases), reminiscent of 
human non-small cell lung cancer148. Tumor burden was compared in KrasLA2/+;Fap+/+, 
KrasLA2/+;Fap+/-, and KrasLA2/+;Fap-/- mice at 12 and 18 weeks of age. At 12 weeks, 
KrasLA2/+;Fap-/- mice exhibited diminished lung tumor burden compared to KrasLA2/+;Fap+/+ 
and KrasLA2/+;Fap+/- mice. However, a gene dosage effect was not observed in this 
model, as KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- lungs had nearly equivalent tumor burden 
(Fig. 11A-B). Therefore, given the high variability of lung tumor burden in this model 
(reflecting the stochastic nature of tumor initiation), data were combined from 
KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- mice for most analyses, thereby focusing the 
comparison on KrasLA2/+;Fap+ (KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/-) versus KrasLA2/+;Fap- 
(KrasLA2/+;Fap-/-) mice. Lung tumor burden was reduced by 37% in KrasLA2/+;Fap- versus 
KrasLA2/+;Fap+ mice (Fig. 11C). The multiplicity of lung tumors did not differ between 
KrasLA2/+;Fap- and KrasLA2/+;Fap+ mice (Fig. 11D). Instead, this difference in tumor burden 
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was attributed to a reduced frequency of large tumors (> 0.5 mm2) in KrasLA2/+;Fap- mice 
(Fig. 11E). These results suggest that FAP promotes tumor growth, but not initiation, in 
this model.  
 
Figure 11. Fap genetic deletion attenuates lung tumor burden in 12-week-old 
KrasLA2/+ mice.   
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Representative H&E staining (A) and quantification of % tumor/lung area (B-C), tumor 
number (D), and incidence of large tumors (E; % tumors > 0.5 mm2) in KrasLA2/+;Fap+/+ 
(n=20 mice), KrasLA2/+;Fap+/- (n=13 mice), and KrasLA2/+;Fap-/- (n=18 mice) lung tissue 
sections. Combined KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- (depicted as Fap+), n = 33 mice. 
Bar graphs depict mean +/- SEM; * p < 0.05; ** p < 0.01. 
 
The role of FAP at later stages of lung tumorigenesis was investigated by 
comparing the tumor burden in KrasLA2/+;Fap+/+, KrasLA2/+;Fap+/-, and KrasLA2/+;Fap-/- mice 
at 18 weeks of age. Of note, 5 mice (1 KrasLA2/+;Fap+/+, 3 KrasLA2/+;Fap+/-, and 1 
KrasLA2/+;Fap-/-) in the allocated cohort of mice for this analysis (a total of 12 
KrasLA2/+;Fap+/+, 13 KrasLA2/+;Fap+/-, and 11 KrasLA2/+;Fap-/- mice) succumbed before 
reaching 18 weeks of age, and were therefore excluded from analysis. Similar to the 12-
week timepoint, KrasLA2/+;Fap-/- mice exhibited diminished lung tumor burden compared 
to KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- mice at the 18-week timepoint; meanwhile, 
KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- mice had nearly equivalent lung tumor burden (Fig. 
12A-B). Taken together, KrasLA2/+;Fap- mice exhibited a 50% decrease in lung tumor 
burden compared to KrasLA2/+;Fap+ (KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- combined) mice 
at 18 weeks of age (Fig. 12C). At this later timepoint, diminished lung tumor burden in 
KrasLA2/+;Fap- mice was attributed to reductions in tumor multiplicity, average tumor size, 
and incidence of large tumors (> 0.5 mm2) (Fig. 12D-F). Consistent with the 12 week 
timepoint, the increased frequency of large tumors at 18 weeks of age in KrasLA2/+;Fap+ 
mice suggests that FAP promotes lung tumor growth.  
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Figure 12. Fap genetic deletion attenuates tumor multiplicity, size, and total tumor 
burden in the lungs of 18-week-old KrasLA2/+ mice.   
Representative H&E staining (A) and quantification of % tumor/lung area (B-C), tumor 
number (D), average tumor area (E; in mm2), and incidence of large tumors (F; % tumors 
> 0.5 mm2) in KrasLA2/+;Fap+/+ (n = 11 mice), KrasLA2/+;Fap+/- (n = 10 mice), KrasLA2/+;Fap-/- 
(n = 10 mice) lung tissue sections. Combined KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- 
(depicted as Fap+), n = 21 mice. Bar graphs depict mean +/- SEM. * p < 0.05; ** p < 
0.01; *** p < 0.001. 
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The role of FAP in lung tumor progression was assessed by comparing the 
frequency of hyperplasias, adenomas, and adenocarcinomas in KrasLA2/+;Fap+/+ versus 
KrasLA2/+;Fap-/- lung tissue sections. At both 12 and 18 weeks of age, KrasLA2/+;Fap+/+ and 
KrasLA2/+;Fap-/- lungs harbored the same number of hyperplasias, further substantiating 
the conclusion that FAP does not regulate tumor initiation in this model. However, at 18 
weeks of age, the incidence of adenomas was significantly reduced in KrasLA2/+;Fap-/- 
versus KrasLA2/+;Fap+/+ lungs (Fig. 13). These results indicate that Fap genetic deletion 
restrains lung tumor progression and the incidence of adenomas. The frequency of 
adenocarcinomas at these timepoints was too low to ascertain the role of FAP in 
regulating adenoma-to-adenocarcinoma progression.   
 
Figure 13. Fap genetic deletion restrains tumor progression in the KrasLA2/+ model 
of lung tumorigenesis.  
Quantification of the frequency of hyperplasias, adenomas, and adenocarcinomas in 
lung tissue sections from 12- and 18-week-old KrasLA2/+;Fap+/+ and KrasLA2/+;Fap-/- mice. 
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12-week-old KrasLA2/+;Fap+/+, n = 10 mice; 12-week-old KrasLA2/+;Fap-/-, n = 9 mice; 18-
week-old KrasLA2/+;Fap+/+, n = 11 mice; 18-week-old KrasLA2/+;Fap-/-, n = 11 mice. Bar 
graph depicts the mean +/- SEM; * p < 0.05. 
 
To further investigate the role of FAP in regulating lung tumorigenesis in the 
KrasLA2/+ model, intratumoral proliferation was assessed. Using Ki67 
immunohistochemistry (IHC), the proliferative indices of KrasLA2/+;Fap+/+, KrasLA2/+;Fap+/-, 
and KrasLA2/+;Fap-/- tumors were measured at the 18-week timepoint. Compared to 
KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- tumors, KrasLA2/+;Fap-/- tumors exhibited 
approximately a 50% reduction in proliferation at the 18-week timepoint (Fig. 14A-B). 
Reflecting the comparable tumor burden in KrasLA2/+;Fap+/+ and KrasLA2/+;Fap+/- lungs, no 
difference in proliferation was observed in KrasLA2/+;Fap+/+ versus KrasLA2/+;Fap+/- tumors. 
The attenuated proliferative indices of KrasLA2/+;Fap-/- tumors help explain the decreased 
tumor burden, incidence of large tumors, and average tumor size in KrasLA2/+;Fap-/- mice 
at this timepoint. Thus, Fap genetic deletion slows tumor growth in the KrasLA2/+ model by 
curtailing intratumoral proliferation.  
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Figure 14. Fap genetic deletion restrains lung tumor proliferation.  
Representative images (A) and quantification (B) of Ki67 IHC staining of KrasLA2/+;Fap+/+ 
(n = 153 tumors, pooled from 11 mice), KrasLA2/+;Fap+/- (n = 98 tumors, pooled from 10 
mice), and KrasLA2/+;Fap-/- (n = 86 tumors, pooled from 10 mice) lung tumors from 18-
week-old mice. Proliferative index was calculated by the ratio of Ki-67+ to hematoxylin+ 
nuclei. Bar graph depicts the mean +/- SEM; **** p < 0.0001. 
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To investigate the role of FAP-mediated ECM remodeling in lung tumorigenesis, 
the desmoplastic response was compared in KrasLA2/+;Fap+/+ versus KrasLA2/+;Fap-/- 
tumors. Picro Sirius Red staining of lung tumors was visualized under polarized light to 
image intratumoral fibrillar collagen. Within KrasLA2/+;Fap+/+ and KrasLA2/+;Fap-/- tumor 
nests, very little fibrillar collagen was detected. Instead, most fibrillar collagen localized 
to the tumor-stromal interface at the tumor periphery. In these areas, more fibrillar 
collagen tended to accumulate in KrasLA2/+;Fap-/- versus KrasLA2/+;Fap+/+ tumors (Fig. 15).  
 
Figure 15. Fibrillar collagen accumulates at the tumor-stromal interface in 
KrasLA2/+;Fap-/- tumors.   
Representative images (acquired under brightfield or polarized light settings) of 
KrasLA2/+;Fap+/+ (n = 6 mice) and KrasLA2/+;Fap-/- (n = 6 mice) lung tumor sections (from 
18-week-old mice) stained with Picro Sirius Red to visualize fibrillar collagen structure.  
White arrows point at fibrillar collagen accumulation at the tumor-stromal interface. 
 
Fap-/- fibroblast-derived matrices (FDMs) restrain tumor cell proliferation and 
motility.  
Considering the correlation between enhanced collagen accumulation and 
reduced proliferation observed in Fap-/- tumors in a variety of different tumor models 
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(including the spontaneous KrasLA2/+ model, the inducible LSL-KrasG12D/+ model, and 
various transplanted tumor models25), we hypothesized that FAP-dependent ECM 
remodeling regulates tumor proliferation directly or indirectly (for example, by regulating 
retention, presentation, and/or activation of soluble factors). The degradation of collagen 
may expose cryptic binding sites that influence tumor cell behavior. Alternately, the 
promotion of collagen internalization by FAP proteolysis may remove modulating growth 
signals from the ECM. Lastly, collagen fragmentation may dictate how fibroblasts 
contract and remodel ECM, which consequently influences the mechanical and/or 
architectural properties of intratumoral ECM (Fig. 16).   
 
 
Figure 16. Possible mechanisms by which FAP-dependent collagen proteolysis 
may regulate ECM remodeling, and consequently, tumor growth. 
 
A variety of different in vitro experimental approaches were employed to test 
these potential mechanisms. First, we tested the hypothesis that FAP-mediated 
proteolysis of ¼ and ¾ collagen fragments eliminates bioactive fragments or generates 
products with distinct bioactivities. Purified type I collagen was first digested in vitro with 
recombinant MMP-1 alone or sequentially by MMP-1, then recombinant FAP 
extracellular domain (Fig. 17A). Murine lung carcinoma cells, including Lewis lung 
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carcinoma (LLC1; derived from a spontaneous lung carcinoma in a C57/BL6 mouse149) 
and K-ras mutant lung adenocarcinoma (LKR13; derived from a KrasLA1/+ mouse148,150) cell 
lines, were seeded on tissue culture-treated plastic and treated with either MMP-1-
digested- or MMP-1 and FAP-digested type I collagen. Treatment with variable 
concentrations of these collagen fragments did not modulate proliferation of either cell 
line (Fig. 17B). LKR13 cells were also cultured on type I collagen gels in the presence or 
absence of MMP-1 +/- FAP. However, addition of MMP-1 and/or FAP did not alter tumor 
proliferation (Fig. 17C). Taken together, these experiments suggest that FAP-mediated 
collagen proteolysis does not directly impact tumor proliferation by generating or 
degrading bioactive type I collagen fragments.  
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Figure 17. Lung tumor cells proliferate equally well in the presence of collagen I 
digested by MMP-1 alone or by MMP-1 and FAP.  
LLC or LKR13 lung adenocarcinoma cells were seeded on plastic, treated with or 
without 5, 10, or 20 μg/ml of type I collagen fragments (A; digested by MMP-1 alone or 
sequentially with MMP-1 and FAP), and counted after 72 hours of treatment (B). (C) 
LKR13 cells were seeded on 1 mg/ml type I collagen gels, treated with or without MMP-1 
(500 ng/ml) +/- FAP (3 nM), and counted after 72 hours of treatment. Bar graphs depict 
the mean +/- SEM of three replicate wells per condition.  
 
Recent studies have demonstrated that Fap+/+ primary lung fibroblasts internalize 
type I collagen more efficiently than Fap-/- fibroblasts, indicating that FAP participates 
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directly in fibroblast-dependent collagen catabolism and clearance24. Considering these 
recent findings, we hypothesized that FAP-dependent collagen proteolysis facilitates 
tumor-promoting, fibroblast-dependent ECM remodeling. To test this hypothesis, we 
compared the composition and influence on tumor cell behavior of FDMs deposited by 
Fap+/+ versus Fap-/- lung fibroblasts.  
Using two-photon second harmonic generation imaging, a two-fold enhancement 
of fibrillar collagen accumulation was observed in ECM deposited by Fap-/- versus Fap+/+ 
fibroblasts (Fig. 18A-B). Furthermore, Fap-/- lung FDMs exhibited higher hydroxyproline 
content (a surrogate assessment of total collagen levels) than Fap+/+ FDMs (Fig. 18C). In 
contrast, our preliminary assessment of FN deposition showed roughly equivalent levels 
in Fap-/- versus Fap+/+ FDMs, suggesting that FAP may selectively regulate fibrillar 
collagen, rather than total ECM accumulation (Fig. 18D). Furthermore, FDM-producing 
Fap+/+ and Fap-/- fibroblasts exhibited roughly equivalent patterns of αSMA expression, 
suggesting that these differences in collagen accumulation do not result from varying 
states of myofibroblast activation between isolated Fap+/+ and Fap-/- fibroblast 
populations under these culture conditions (Fig. 18E). Rather, the impaired capacity of 
Fap-/- fibroblasts to degrade and turn over fibrillar collagen24 likely explains the enhanced 
collagen accumulation in Fap-/- FDMs. Thus, Fap-/- FDMs recapitulate the collagen 
accumulation observed in Fap-/- versus Fap+/+ lungs in murine models of lung 
tumorigenesis and fibrosis24,25.  These results validate this in vitro system as a model to 
study the effect of collagen accumulation (due to Fap deletion) on tumor cell behavior.  
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Figure 18. Fap-/- lung fibroblasts deposit FDMs with enhanced fibrillar collagen 
accumulation.  
Representative images (A) and quantification (B) of fibrillar collagen (visualized via two-
photon SHG microscopy) and quantification of total collagen (C; assessed via 
hydroxyproline assay) in Fap-/- versus Fap+/+ FDMs. Results were compiled from 4 
independent experiments and the bar graphs depicts the means of experiments +/- 
SEM; * p < 0.05; ** p < 0.01. Representative images of FN (D) and αSMA (E) IF staining 
of Fap+/+ versus Fap-/- FDMs (before de-cellularization). N = 2 FDMs per genotype.  
 
To investigate the role of FAP-dependent fibroblast-mediated ECM remodeling in 
the regulation of tumor cell proliferation, LKR13 lung adenocarcinoma cells were 
cultured on Fap+/+ versus Fap-/- FDMs.  LKR13 proliferation on FDMs (in 1% serum) was 
assessed following an 8-hour pulse with 5-ethynyl-2-deoxyuridine (EdU), a thymidine 
analog incorporated into DNA during active DNA synthesis151. Compared to Fap+/+ 
FDMs, Fap-/- FDMs hindered LKR13 proliferation, as indicated by a reduction in cell 
number (measured via Hoescht staining of nuclei) and EdU uptake (Fig. 19A). Pooling 
data from 3 independent experiments showed that tumor cell count and proliferation 
were attenuated by 40% and 20%, respectively, on Fap-/- versus Fap+/+ FDMs (Fig. 19B). 
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Statistical significance will need to be determined with additional experimental replicates. 
Similarly, additional lung tumor cell lines should be investigated to definitively establish 
that Fap-/- FDMs consistently restrain lung tumor cell proliferation.  
 
Figure 19. Fap-/- FDMs restrain lung tumor cell proliferation.  
LKR13 tumor cells were cultured in 1% serum on Fap+/+ versus Fap-/- FDMs for 24 hours 
(with 10 μM EdU for the final 8 hours). Quantification of cell count (left; average number 
of Hoechst+ nuclei per 10X field) and proliferative index (right; % Edu+ / Hoechst + nuclei) 
from a representative experiment (A) and compiled data from 3 independent 
experiments (B). Graphs depict the means +/- SEM (n = 3 FDMs in A; n = 3 independent 
experiments in B); * p < 0.05; ** p < 0.01. 
Prior studies demonstrated that CAFs can enhance the invasion of carcinoma 
cells via a mechanism dependent on MMP activity and Rho-mediated contraction of the 
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matrix75. Furthermore, another study found that FAP-overexpressing NIH-3T3 fibroblasts 
produce highly aligned ECMs that enhanced the directionality and velocity of pancreatic 
cancer cell migration152. Therefore, we compared tumor cell motility on Fap+/+ versus 
Fap-/- pulmonary FDMs to investigate the potential role of FAP-dependent ECM 
remodeling in lung tumor invasion and metastasis. Lung (LKR13) and metastatic human 
breast (MDA-MB-231153) adenocarcinoma cell lines were utilized to simulate 
intrapulmonary migration of primary and metastatic tumor cells, respectively. Preliminary 
experiments demonstrated that Fap-/- versus Fap+/+ lung FDMs impeded the trajectory 
(total distance traveled), but not the directionality, of lung and breast tumor cell migration 
(Fig. 20A-B). These experiments provide preliminary evidence that FAP-mediated ECM 
remodeling can directly promote tumor cell migration.  
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Figure 20. Fap-/- FDMs restrain tumor cell motility.  
Trajectory (left; in microns) and directionality (right; displacement/trajectory) of MDA-MB-
231 (A) or LKR13 (B) migration were tracked on Fap+/+ versus Fap-/- FDMs for 6 hours. 
Bar graphs depict mean +/- SEM; * p < 0.05; **** p < 0.0001. In A, n = 100 cells per 
condition (compiled from 3 FDMs) and results depict 1 representative experiment (of 2 
experiments). In B, n = 30 cells per condition (compiled from 3 FDMs) and results depict 
data from 1 experiment.  
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Discussion 
 In summary, I have shown that Fap genetic deletion curbs tumor growth in the 
spontaneous KrasLA2/+ model, but not the highly desmoplastic LSL-KrasG12D/+Tgfbr2flox/flox 
model of lung tumorigenesis. Highly aggressive LSL-KrasG12D/+Tgfbr2flox/flox tumors147 may 
have overcome the tumor suppressive microenvironment evident in Fap-/- lungs in other 
tumor models, including the LSL-KrasG12D/+ model25 and the KrasLA2/+ model. Of note, 
tumor burden was assessed relatively late (8 weeks post-tumor initiation), and 
differences in tumor growth kinetics in Fap+/+, Fap+/-, and Fap-/- lungs may have been 
missed. Therefore, assessment of tumor burden at earlier timepoints in this model is 
warranted.   
In the KrasLA2/+ model, the diminished lung tumor burden in KrasLA2/+Fap-/- mice at 
18 weeks of age was attributed to reductions in tumor multiplicity, size, progression, and 
proliferation. Notably, an attenuation in lung tumor multiplicity was observed in 
KrasLA2/+;Fap- versus KrasLA2/+;Fap+ mice at 18, but not 12, weeks of age. Intrapulmonary 
metastatic dissemination may explain this discrepancy. Definitively proving this 
hypothesis would require karyotyping of individual tumors. In KrasLA2/+;Fap+ versus 
KrasLA2/+;Fap- lungs, the comparable number of total tumors at the 12-week timepoint as 
well as the comparable number of hyperplasias at both the 12- and 18-week timepoints 
suggests that FAP does not regulate tumor initiation in this model.  However, 
assessment at earlier timepoints is warranted to more definitively validate this 
conclusion. Furthermore, future experiments should assess intratumoral EdU 
incorporation to more definitively establish that Fap genetic deletion restrains 
intratumoral proliferation.  
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Picro Sirius Red staining revealed increased fibrillar collagen accumulation at the 
tumor-stromal interface of KrasLA2/+Fap-/- versus KrasLA2/+Fap+/+ tumors, corroborating the 
enhanced collagen accumulation (as assessed via hydroxyproline assay) in Fap-/- versus 
Fap+/+ lungs in the LSL-KrasG12D/+ lung tumor model25. Using FDMs as a reductionist 
approach, my preliminary data suggest that Fap-/- pulmonary fibroblasts accumulate a 
fibrillar collagen-rich ECM that directly attenuates tumor cell proliferation and migration, 
compared to growth on Fap+/+ FDM. These results offer further support for my hypothesis 
that FAP-dependent collagen proteolysis and ECM remodeling directly promote tumor 
cell proliferation and invasion.  
Both in vivo (KrasLA2/+ mice) and in vitro (FDMs) models require further analyses 
to more carefully delineate FAP-dependent changes to ECM (including its architecture, 
mechanics, biochemical modifications, and composition) and ECM-dependent signaling 
(including integrin- and discoidin domain receptor-mediated pathways) to uncover 
specific mechanisms by which FAP-dependent ECM modification regulates 
tumorigenesis. For example, the fibrillar collagen that accumulates in Fap-/- tumors and 
FDMs should be characterized. Closer examination of the gene expression profile of 
FAPHi fibroblasts (Table 2) revealed approximately two-fold higher levels of Col3a1 than 
Col1a1. Thus, COL 3 might constitute the majority of the fibrillar collagen accumulating 
in Fap-/- ECM. A recent study from our collaborators (the laboratory of Dr. Susan Volk) 
demonstrated that COL 3 suppresses primary tumor growth and metastasis144. 
Specifically, in an orthotopic model of breast cancer, they demonstrated accelerated 
primary tumor growth and heightened pulmonary metastatic burden in Col3a1+/- versus 
Col3a1+/+ mice. Furthermore, in vitro experiments demonstrated that COL 3 directly 
impairs breast cancer cell invasion and that breast cancer cells proliferate more on 
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Col3a1-/- versus Col3a1+/+ FDMs144. Thus, impaired collagen degradation and clearance 
in Fap-/- tumors might directly impede tumor proliferation and invasion by causing the 
excessive accumulation of tumor-inhibitory COL 3.  
Taken together, these studies offer further support for FAP as a drug target for 
the treatment of lung cancer. Importantly, these studies also highlight the complexity of 
intratumoral desmoplasia in the regulation of tumorigenesis. As discussed in chapter 1, 
intratumoral ECM can promote or impede tumorigenesis, often depending on its 
composition and degradative state. Thus, rather than eliminate intratumoral 
desmoplasia, novel stroma-targeted therapeutic strategies might aim to enrich for the 
tumor-inhibitory components of ECM for optimal cancer treatment, and perhaps even 
prevention.  
Methods 
Animals 
Fap-/- mice (Fap-luciferase; FapLuc/Luc) were generated by modifying a targeting 
construct provided by Dr. Andreas Schnapp at Boehringer-Ingelheim. LA2–KrasG12D/+ 
mice (KrasLA2/+; provided by Dr. Joseph Kissil) were crossed with FAPLuc/Luc mice to 
generate littermate KrasLA2/+FapLuc/Luc, KrasLA2/+FapLuc/+, and KrasLA2/+Fap+/+ mice. LSL-
KrasG12D/+Tgfbr2flox/flox (provided by Dr. Steven Albelda) were crossed with FapLuc/Luc mice 
to generate littermate LSL-KrasG12D/+;Tgfbr2flox/flox;Fap+/+, LSL-KrasG12D/+;Tgfbr2flox/flox; 
Fap+/Luc, and LSL-KrasG12D/+;Tgfbr2flox/flox;FapLuc/Luc mice.  
 Genotyping 
The following primer sequences were used for genotyping. Fap: 5’-
CAGCTGTGCTTTATGGGTTT, 5’-CCCTCGAAGGCCTACTAATC, and 5’-
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ATCTCTCGTGGGATCATTGT. KrasLA2: 5’-TGCACAGCTTAGTGAGACCC, 5’-
GACTGCTCTCTTTCACCTCC, 5’-GGAGCAAAGCTGCTATTGGC. Tgfbr2flox: 5’-
TAAACAAGGTCCGGAGCCCA, 5’-ACTTCTGCAAGAGGTCCCCT. LSL-KrasG12D: 5’- 
CCATGGCTTGAGTAAGTCTGC, 5’- CGCAGACTGTAGAGCAGCG.  
Tumor models 
For the KrasLA2/+ tumor model, male and female mice were sacrificed at 12 or 18 
weeks of age. For the LSL-KrasG12D/+Tgfbr2flox/flox model, tumor initiation was induced in 
12-to-14-week-old male or female mice via intranasal administration of 100 uL MEM 
containing 5x107 plaque forming units of adenovirus expressing cre recombinase 
(University of Iowa). Approximately 15 minutes before viral administration, 0.5 μl CaCl2 
was added to improve gene transfer147. LSL-KrasG12D/+Tgfbr2flox/flox mice were sacrificed 8 
weeks after initiating tumorigenesis via adenoviral administration. In both tumor models, 
after mice were euthanized, the pulmonary circulation was perfused with PBS via 
intracardiac injection. Lungs were then fixed via intratracheal instillation of Prefer 
(Anatech) and resected. All 5 lung lobes were fixed overnight in Prefer, dehydrated in 
70% ethanol, and embedded in paraffin. 4 μm sections were cut from 3 distinct cross-
sectional areas of lung tissue.  
Assessment of lung tumor burden  
For each sample, 4 μm sections (from 3 distinct cross-sectional areas of the 
lung) were stained with hematoxylin and eosin. Images were obtained at 2X 
magnification using an Olympus BX51 upright microscope and image stitching was 
performed using Photoshop (Adobe). Quantification of tumor burden (percent tumor-to-
lung area), tumor number, and tumor area was performed using FIJI software.   
66 
 
Dichrome staining 
Tissue sections were de-paraffinized, rehydrated, and incubated with Bouin’s 
solution (Rowley Biochemicals) overnight at room temperature (RT). After washing 
slides with running tap H2O to remove yellow color, slides were stained with Biebrich 
Scarlet-Acid Fuschin (Rowley Biochemicals) for 5 minutes, washed with deionized H2O 
for 5 minutes, and then placed in Phosphotungstic/Phosphomolybdic Acid (Rowley 
Biochemicals) solution for 20 minutes at RT. Sections were stained with Aniline Blue 
(Rowley Biochemicals) for 10 minutes, dipped in 1% acetic acid at RT, and rinsed in 
deionized H2O. Slides were then dehydrated, cleared in Clear-Rite 3, and mounted in 
Cytoseal XYL. Images were obtained at 10X magnification using an Olympus BX51 
upright microscope. 
Ki67 immunohistochemistry  
After de-paraffinizing and re-hydrating tissue sections, antigen retrieval was 
performed in 10 mM sodium citrate buffer (pH 7.4) for 20 minutes at 95°C. Endogenous 
peroxidase activity was quenched with 3% hydrogen peroxide for 15 minutes at RT. 
Sections were blocked with 10% normal goat serum in 1% BSA for 15 minutes at RT. 
Endogenous avidin and biotin were blocked using the avidin-biotin kit (Vector Labs). 
Sections were incubated with Ki67 antibody (Abcam, clone SP6, 1:100) overnight at 4°C, 
followed by a 1 hour incubation with biotinylated goat anti-rabbit antibody (Vector Labs, 
BA-1000) at RT. Bound antibodies were detected with horseradish peroxidase using the 
Vectastain Elite ABC kit (Vector Laboratories) and sections were counterstained with 
hematoxylin. Slides were then dehydrated, cleared in Clear-Rite 3, and mounted in 
Cytoseal XYL. Digital images of the entirety of every tumor in each tissue section were 
taken at 20X magnification using an Olympus BX51 upright microscope and image 
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stitching was performed using Photoshop (Adobe). Quantification was performed using 
FIJI software. Proliferative index was calculated by the ratio of Ki-67+ cells to 
hematoxylin+ cells.  
Picro Sirius Red staining  
Tissue sections were de-paraffinized, rehydrated, and stained with 0.1% Picro 
Sirius Red solution (Direct Red-80 in picric acid) at RT. Slides were then washed in 
acidifed water (0.5% glacial acetic acid), dehydrated, cleared in Clear-Rite 3, and 
mounted in Cytoseal XYL. Images were obtained under brightfield or polarized light at 
10X magnification using a Nikon Eclipse E600 microscope.  
Collagen digests  
Rat tail type I collagen gels (BD Biosciences) were sequentially digested with 
recombinant human MMP-1 (R&D Systems) and/or recombinant murine FAP 
extracellular domain (ECD), as described previously24. Collagen digests were prepared 
for electrophoresis by adding 4X NuPAGE sample buffer and reducing agent and 
heating at 70°C for 10 minutes. Equivalent volumes of the collagen digests were 
resolved on a 4–12% Bis-Tris gel (Invitrogen) with MES running buffer. Undigested, 
acid-solubilized rat tail type 1 collagen was also included as a reference for intact 
collagen. The gel was stained with SimplyBlue SafeStain (Invitrogen), washed in water, 
and photographed. 
Proliferation assays with collagen fragments 
 LLC and LKR13 lung adenocarcinoma cells were seeded in 10% serum in tissue 
culture-treated 96-well plates with or without 5, 10, or 20 μg/ml MMP-1- or MMP-1/FAP-
digested collagen fragments. 3 replicates were seeded per condition. 72 hours later, 
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cells were trypsinized, quenched with 10% serum, and enumerated using a Z Series 
Coulter Counter (Beckman Coulter Life Sciences).   
Proliferation assays on collagen gels with recombinant MMP-1 +/- FAP ECD 
96-well plates were coated with 30 μL of 1 mg/ml neutralized rat tail type I 
collagen (BD Biosciences) and incubated for 1 hour at 37°C to facilitate collagen 
polymerization. LKR13 cells were seeded on collagen gels in 10% serum +/- MMP-1 
(500 ng/ml) +/- FAP ECD (3 nM). 3 replicates were seeded per condition. 72 hours later, 
wells were washed in PBS and then incubated in 150 μl collagenase solution [1.5 mg/ml 
type IV collagenase (Worthington), 2 mM EDTA (Gibco), and 200 μg/ml DNase (Roche) 
in DMEM) for 20 minutes at 37°C to obtain a single cell suspension. Cells were counted 
using a Z Series Coulter Counter.  
Lung fibroblast isolation (digest method) 
See description of method in chapter 2. 
Fibroblast-derived matrices (FDMs) 
See description of method in chapter 2. 
2-photon second harmonic generation imaging of fibrillar collagen 
Imaging of fibrillar collagen in decellularized fibroblast-derived matrices was 
based on second harmonic generation (SHG) utilizing a Leica SP5 confocal/multiphoton 
microscope (Leica Microsystems) as described previously144. 
Hydroxyproline assay 
See description of method in chapter 2. 
Immunofluorescence 
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After depositing FDMs for 8 days, lung fibroblasts were fixed with 4% 
paraformaldehyde, permeabilized with 0.05% Triton-X-100, blocked with 5% BSA, and 
incubated with rabbit anti-FN antibody (Sigma, Clone F3648) and anti-αSMA antibody 
(Sigma, clone1A4, FITC), followed by AF658 goat anti-rabbit antibody (Invitrogen) and 
DAPI. 
EdU proliferation assay on FDMs  
Before seeding tumor cells, FDMs were blocked with heat-denatured BSA for 1 
hour at 37°C and then washed twice with PBS. LKR13 lung adenocarcinoma cells were 
seeded on FDMs (3 replicate wells per condition) in 1% serum and allowed to adhere 
overnight at 37°C. The next day, 10 μM EdU was added. After an 8-hour incubation with 
EdU at 37°C, cells were fixed with 4% PFA. EdU+ and total nuclei were detected using 
the Click-iT EdU Imaging Kit (Invitrogen) and Hoechst staining, respectively.  Images 
were obtained in 5 random 20X fields per well (for quantification of proliferative index) 
and 5 random 10X fields per well (for quantification of cell count) using an Olympus 
CKX41 inverted microscope. Quantification was performed using FIJI software. 
Proliferative index was calculated by the ratio of EdU+ nuclei to total Hoechst+ nuclei and 
cell count was measured as the average number of Hoescht+ nuclei per 10X field.  
Time lapse motility assays on FDMs 
 Before seeding tumor cells, FDMs were blocked with heat-denatured BSA for 1 
hour at 37°C and then washed twice with PBS. LKR13 or MDA-MB-231 were seeded at 
low confluence in 10% FCS DMEM (3 replicate wells per condition) and allowed to 
adhere to FDMs overnight at 37°C. The next day, the 6-well plate was put on an 
environmentally controlled microscope stage and allowed to equilibrate for at least 30 
minutes. Cell movements were then recorded with a Leica DMI4000 microscope by 
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acquiring a phase contrast image every 10 minutes for 6 hours in 10-12 randomly 
chosen 10X fields per well. Volocity software was used to track migration of individual 
cells, including the net path distance (D, μm), path trajectory (T, μm), and directionality 
(calculated by the D/T ratio). As recommended by established protocols154, cells that 
underwent cell division or collided with other cells were excluded from analysis, since 
these events can interfere with the rate and directionality of cell migration.  
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CHAPTER FOUR: CONCLUSIONS AND FUTURE DIRECTIONS 
 
In this dissertation, I delineated the regulation and potentially unique functionality 
of heterogeneous activated fibroblast subsets. My studies revealed that ECM mechanics 
and composition regulate fibroblast activation to the FAPHi reactive fibroblast versus 
αSMAHi myofibroblast phenotype. Moreover, I defined gene expression signatures for 
FAPHi and αSMAHi fibroblasts, which suggest that these subsets may exert unique 
functional roles in tissue remodeling. Lastly, my studies provide novel insights into the 
mechanisms by which FAP proteolytic activity regulates ECM composition to promote 
tumorigenesis.    
Regulation and functionality of heterogenous fibroblast subsets in actively 
remodeling tissues 
The divergent outcomes in response to varied therapies targeting CAFs 
(discussed at length in chapter one) emphasize the urgent need to delineate the unique 
roles of CAF subsets. The data obtained in this dissertation address this gap in 
knowledge. Specifically, we sought to uncover the unique regulation and functionality of 
αSMAHi and FAPHi CAFs in tumorigenesis. 
Importantly, the emergence of αSMAHi and FAPHi fibroblast subsets is not 
restricted to tumorigenesis. Rather, activated fibroblast heterogeneity arises in virtually 
all conditions associated with active tissue remodeling, including fibrosis and wound 
healing. Since tumors are often characterized as “wounds that never heal”1, we 
hypothesized that similar mechanisms direct fibroblast heterogeneity in both wound 
healing and cancer. In acute injury, plasma extravasation from damaged blood vessels 
deposits a provisional matrix, consisting mostly of fibrin and FN. This provisional matrix 
72 
 
facilitates migration of diverse cell types into the wound. The injury response is highly 
regulated, and consists of three sequential phases: (1) inflammation, (2) tissue formation 
(including re-epithelialization, ECM deposition, and neovascularization), and (3) ECM 
remodeling and contraction. During the process of wound healing, provisional matrix 
gradually evolves into collagen-rich connective tissue109. Analogous evolution of the 
ECM occurs during tumorigenesis. Highly permeable tumor microvasculature promotes 
plasma fibrinogen and FN deposition.  As in granulation tissue, intratumoral desmoplasia 
evolves from provisional fibrin and FN-rich ECM into mature, collagenous ECM1,2.  
Therefore, we hypothesized that the transformation of a provisional FN-rich ECM 
into mature COL 1-rich ECM directly regulates the spatiotemporal heterogeneity of 
activated fibroblasts noted in these contexts. Using FN- and COL1-coated hydrogels of 
varying stiffness, we discovered that ECM composition, stiffness, and TGF-β 
coordinately regulate activated fibroblast heterogeneity. On soft, FN-rich ECMs, TGF-β 
promotes the FAPHiαSMALow reactive fibroblast phenotype. Conversely, TGF-β promotes 
the FAPLowαSMAHi myofibroblast phenotype on stiff and/or COL 1-rich ECMs (Fig. 9).  
Comparable regulation and diversification of functionality of fibroblast subsets 
likely occurs in injury and tumorigenesis. For clarification, we center our working model 
on the acute injury response, due to its well-characterized and highly regulated 
progression (Fig. 21). In early wounds, the soft, FN-rich environment likely promotes 
FAPHi fibroblast differentiation. The gene expression profile of FAPHi fibroblasts suggests 
that they orchestrate early phases of wound resolution by secreting: (1) ECM proteases 
to facilitate cell migration into the wound, (2) paracrine growth factors to support re-
epithelialization, and (3) ECM and matricellular components to replace provisional ECM 
with COL1-rich connective tissue. Thereafter, the stiff, COL1-rich environment of late 
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granulation tissue likely promotes αSMAHi myofibroblast differentiation. Contractile, 
αSMAHi myofibroblasts orchestrate the late phases of wound resolution, including fibro-
proliferation (by secreting autocrine growth factors) and wound closure.  
 
Figure 21. Working model depicting the proposed regulation and functionality of 
FAPHi and αSMAHi fibroblast subsets in the injury response.   
 
Recent evidence from our laboratory substantiates this proposed model. We 
observed spatiotemporal regulation of fibroblast heterogeneity in cutaneous wound 
healing. Temporally, FAP expression peaks around day 7 post-injury, while αSMA 
expression peaks around day 11. Spatially, most FAPHi activated fibroblasts reside in the 
hypodermis, and most αSMAHi myofibroblasts reside in the dermis (Govindaraju, et al.; 
manuscript in preparation). Furthermore, we observed comparable spatial heterogeneity 
of smooth muscle cell (SMC) populations in atherosclerotic plaques. αSMAHi SMCs 
74 
 
localize mostly to the collagen-rich fibrous cap, while FAPHi SMCs accumulate primarily 
in the lipid-rich plaque interior (Monslow, et al.; manuscript in preparation). These results 
coincide with the divergent spatiotemporal patterns of FAP and αSMA expression 
observed in diverse contexts (discussed at length in chapter 1), such as in varied tumor 
types (including breast17, pancreatic55,57, and lung58), fibrotic conditions (including 
idiopathic pulmonary fibrosis12 and liver cirrhosis12), and after acute injury (including 
post-bleomycin-induced lung injury24,48 and post-myocardial infarction11). Across these 
diverse contexts, αSMAHi, but not FAPHi, fibroblasts usually reside in collagen-rich areas, 
which substantiates our working model12,50,51,58. Moreover, the emergence of FAPHi 
fibroblasts usually precedes that of αSMAHi myofibroblasts, further corroborating our 
working model11,24,48,55. Considering these findings in conjunction with recent evidence 
that FAPHi fibroblast depletion eliminates most αSMAHi myofibroblasts, but not vice 
versa16, it seems that FAPHi fibroblasts may play a key role in the generation of αSMAHi 
myofibroblasts.  
Future work should further investigate our proposed model in vivo. Correlations 
between activated fibroblast heterogeneity and ECM composition could be assayed by 
immunofluorescence staining for FAP, αSMA, FN, and COL1 in tumors and granulation 
tissue. Combining FAP and αSMA immunofluorescence with atomic force microscopy 
could assess the relationship between ECM stiffness and fibroblast heterogeneity. 
Lastly, studies could demonstrate in vivo that modifying ECM regulates fibroblast 
heterogeneity. For these studies, intratumoral stiffness can be modified by administering 
β-aminopropionitrile (BAPN) or LOX inhibitors to tumor-bearing mice. Moreover, injecting 
collagenase intratumorally could degrade fibrillar collagen. I predict that BAPN, LOX 
inhibitors, and collagenase treatments would all enrich for FAPHi fibroblasts.  
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Our gene expression profiling data also highlight potentially unique tumor-
modulatory capacities of FAPHi fibroblasts and αSMAHi myofibroblasts. The heightened 
capacity of αSMAHi myofibroblasts to contract and crosslink ECM suggests that they 
further amplify intratumoral stiffness. Given the ample evidence that ECM stiffness 
promotes tumor growth and invasion73,74,112,155, it may therefore appear counterintuitive 
that FAPHi fibroblasts (which prevail under low stiffness conditions) seem to more 
profoundly and consistently promote tumorigenesis than αSMAHi 
myofibroblasts16,55,56,95,96,100,102. Our gene expression data helps explain this apparent 
conundrum, since FAPHi fibroblasts exhibit higher gene expression of many tumor-
promoting ECM proteases, growth factors, and ECM and matricellular components (as 
discussed in chapter 2). Furthermore, coinciding with a recent report of a pro-
tumorigenic, pro-inflammatory, and αSMALow fibroblast phenotype57, our data suggest 
that FAPHi fibroblasts may exhibit a more pro-inflammatory phenotype. However, follow-
up studies will need to more definitively establish this pro-inflammatory phenotype by 
simulating other features of the tumor microenvironment.  
Taken together, these studies are the first to precisely delineate features of 
actively remodeling tissues that drive activated fibroblast heterogeneity. These 
mechanistic insights will help foster the rational design of therapeutic strategies that 
target activated fibroblasts in cancer and fibrosis.  
Fibroblast heterogeneity: A determinant of stroma-targeted therapy efficacy 
 Importantly, our results may help explain the dichotomous results obtained so far 
with different stroma-targeted therapies, such as sonic hedgehog (SHH) pathway 
inhibitors and VDR agonists. In PDAC, SHH pathway inhibition accelerates tumor growth 
and attenuates survival by changing the balance between the epithelial and stromal 
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compartments. Specifically, SHH inhibition accelerates the proliferation of epithelial-
derived tumor cells, but depletes αSMAHi myofibroblasts and type I collagen93,94. Our 
gene expression data illustrated that, compared to αSMAHi myofibroblasts, FAPHi reactive 
fibroblasts express higher mRNA levels of paracrine growth factors supportive of 
epithelial proliferation (such as Egf and Hgf), and lower mRNA levels of autocrine growth 
factors (such as Ctgf, Tgfb2, Tgfb3, and Pdgfa). Since SHH inhibition depletes 
intratumoral αSMAHi myofibroblasts and type I collagen, it may enrich for FAPHi reactive 
fibroblasts that preferentially support epithelial (i.e. tumor cell) proliferation. Therefore, 
future studies should assess changes in intratumoral fibroblast heterogeneity (including 
the relative abundance of αSMAHi and FAPHi fibroblast populations) in response to 
treatment with inhibitors of SHH signaling.  
 Furthermore, our results have important implications for understanding VDR 
agonist-mediated blockade of TGF-β/SMAD signaling as a therapeutic strategy87,88. We 
found that treatment with calcipotriol (a VDR agonist) induced higher expression of 
Cyp24a1 (a VDR target gene) in fibroblasts cultured on 2 versus 20 kPa FN-coated 
hydrogels. Furthermore, calcipotriol fully abrogated high Fap expression on 2 kPa 
hydrogels, but only partially attenuated high Acta2 expression on 20 kPa hydrogels. 
These results indicate that FAPHi fibroblasts are more sensitive to calcipotriol and that 
high ECM stiffness may confer resistance to calcipotriol treatment. Intriguingly, in murine 
models of chronic pancreatitis and PDAC, calcipotriol treatment attenuates the 
expression of many ECM components, inflammatory cytokines, and growth factors, but 
does not significantly alter Acta2 expression88. Therefore, future studies should assess 
changes to intratumoral fibroblast heterogeneity (including the relative abundance of 
αSMAHi and FAPHi fibroblast populations) in response to treatment with calcipotriol. 
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Since recent studies suggest that αSMAHi myofibroblasts may restrain tumor 
aggressiveness56, preferential targeting of tumor-promoting FAPHi fibroblasts may help 
explain the efficacy of calcipotriol in pre-clinical tumor models.   
Investigating the mechanisms underlying ECM-dependent generation of FAPHi 
versus αSMAHi myofibroblasts 
Fully understanding the regulation of heterogenous fibroblast populations will 
foster the rational design of stroma-targeted therapies in cancer. Therefore, future 
studies should delineate the mechanisms underlying the ECM-dependent switch 
between the FAPHi reactive fibroblast and αSMAHi myofibroblast phenotypes. 
Surprisingly, neither FAK nor ROCK activity regulates this phenotypic transition. Based 
on the evidence discussed herein, I propose that changes in ECM composition and 
mechanics directs fibroblast heterogeneity by regulating ligation of specific integrins (Fig. 
22).   
Accessibility of integrin-binding sites in FN depends on mechanical tension. 
Under low stiffness conditions, cells can bind the constitutively exposed RGD site in FN, 
but not the sequestered PHSRN sequence (also known as the synergy site). Increasing 
mechanical tension stretches FN molecules, and consequently exposes the cryptic 
PHSRN motif80,123. Importantly, exposure of the PHSRN sequence regulates integrin 
engagement. αvβ3 binds RGD, but not PHSRN motifs. In contrast, full α5β1 ligation 
requires β1 and α5 binding of RGD and PHSRN, respectively80. Consequently, 
substratum with only accessible RGD sites favors αvβ3 binding, while substratum with 
exposed RGD and PHSRN motifs favors α5β1 binding156. Thus, FN stiffness may dictate 
αvβ3 versus α5β1 engagement in lung fibroblasts by regulating the accessibility of the 
PHSRN motif.  
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A recent study on the regulation of mesenchymal stem cell (MSC) differentiation 
corroborates this hypothesis157. This study demonstrated that modulating the stiffness of 
FN-coated hydrogels controls MSC differentiation by regulating αvβ3 versus α5β1 integrin 
ligation. Specifically, the folded conformation of FN on low stiffness hydrogels 
preferentially engaged αvβ3 integrins, which promoted adipogenic differentiation. In 
contrast, the stretched conformation of FN on high stiffness hydrogels preferentially 
engaged α5β1 integrins, which promoted osteogenic differentiation157. Consequently, I 
propose a similar mechanism underlying fibroblast differentiation, in which ligation of 
αvβ3 promotes FAPHi fibroblast differentiation and ligation of α5β1 promotes αSMAHi 
myofibroblast differentiation (Fig. 22). Follow-up studies can test this proposed 
mechanism by treating lung fibroblasts on FN-coated hydrogels of variable stiffness with 
αvβ3 and α5β1 integrin antagonists.  
Future studies should also explore how COL 1 promotes αSMAHi myofibroblast 
differentiation, even under low stiffness conditions. COL 1’s fibrillar structure may confer 
added stiffness to the underlying hydrogel substratum, which we could test by comparing 
the stiffness of uncoated, FN-coated, and COL1-coated hydrogels via atomic force 
microscopy. In this light, collagen I deposition may similarly stiffen actively remodeling 
tissues in vivo, thereby promoting myofibroblast differentiation. Alternately, the 
constitutively accessible GFOGER sequence in COL 1’s triple helical structure may 
underlie COL 1-induced myofibroblast differentiation, since the GFOGER sequence can 
fully activate α2β1 integrin at any stiffness123. α2β1 integrin recognition of COL 1 through 
the GFOGER motif depends on COL 1 triple helical structure123,158. As MMPs degrade 
COL I, they alter integrin specificity by unwinding COL I triple helices159 and exposing 
cryptic RGD sites59. As a result, β1 and αvβ3 integrins preferentially bind native fibrillar 
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collagen (via the GFOGER sequence) and exposed RGD sites, respectively59,60. 
Therefore, COL 1-induced αSMAHi myofibroblast differentiation on low stiffness 
hydrogels may depend on its triple helical structure. Future studies should compare 
fibroblast differentiation on low stiffness hydrogels coated with fibrillar or denatured 
(either monomeric or proteolyzed) COL 1. I predict that αvβ3 ligation of RGD sites in 
denatured collagen would promote FAPHi fibroblast differentiation, while β1 ligation of 
fibrillar collagen would promote αSMAHi myofibroblast differentiation (Fig. 22). 
 
Figure 22. Proposed mechanisms underlying ECM-dependent generation of FAPHi 
versus αSMAHi fibroblasts in actively remodeling tissues. 
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Considering these hypothesized mechanisms in the context of granulation tissue 
helps clarify this proposed model of ECM-dependent regulation of fibroblast 
heterogeneity (Fig. 22). A FN-rich, low stiffness, and highly proteolytic environment 
characterizes early granulation tissue. Under these conditions, both FN and proteolyzed 
COL 1 present RGD binding sites that preferentially engage αvβ3, which likely promotes 
FAPHi reactive fibroblast differentiation. Meanwhile, a COL 1-rich, high stiffness 
environment characterizes late granulation tissue. Under stiff conditions, FN molecules 
present both RGD and PHSRN motifs, which preferentially engage α5β1 integrins. Intact, 
fibrillar COL 1 molecules present GFOGER motifs, which preferentially engage β1 
integrins. Under these conditions, preferential ligation of β1 integrins likely promotes 
αSMAHi myofibroblast differentiation. Meanwhile, a heterogeneous mixture of αvβ3 and β1 
ligands in the ECM may promote the FAPHiαSMAHi intermediate phenotype. Performing 
the experiments described above will test the mechanisms proposed in this model.  
FAP promotes primary tumor growth and metastasis in diverse tumor types 
In this dissertation, we validated FAP as a drug target in lung cancer by 
demonstrating that FAP promotes tumor progression and proliferation in the 
spontaneous, KrasLA2/+ model of lung tumorigenesis. These results fully corroborate a 
prior report from our laboratory that similarly demonstrated a pro-tumorigenic role of FAP 
in the LSL-KrasG12D/+ lung cancer model25. Taken together, these studies demonstrate 
that FAP proteolytic activity itself constitutes an important mechanism by which FAPHi 
reactive fibroblasts promote tumorigenesis25. Given its role in the ordered proteolytic 
processing of collagen I and III23, we also tested the hypothesis that FAP-mediated ECM 
remodeling directly promotes tumor cell proliferation and invasion.  We found that FAP 
regulates fibrillar collagen accumulation both in vivo and in vitro. Furthermore, we 
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obtained preliminary evidence that compared to Fap+/+ FDMs, fibrillar collagen-rich Fap-/- 
FDMs directly attenuate lung tumor cell proliferation and migration. 
Recently, our laboratory has also demonstrated that FAP accelerates primary 
tumor initiation and growth in the MMTV-HER2/neu model of breast cancer (Blomberg, 
et al., in preparation) and the KPC model of pancreatic ductal adenocarcinoma (Lo, et 
al., in preparation). Furthermore, FAP promotes colonization and metastatic outgrowth of 
transplanted pancreatic, breast, and pulmonary adenocarcinoma cell lines in the lung as 
well as metastatic dissemination to multiple visceral organs in the KPC model (Lo, et al., 
in preparation). Taken together, these studies validate FAP as an attractive drug target 
for the treatment of a variety of tumor types. Future studies should further characterize 
the fibrillar collagen that accumulates in Fap-/- tumors and FDMs. An accumulation of 
tumor-inhibitory COL 3 could help explain how Fap genetic deletion restrains tumor 
growth, invasion, and metastasis.  
ECM: A key player in tumorigenesis 
The work in this dissertation underscores the essential role of ECM remodeling in 
tumor evolution. We demonstrated that ECM regulates key aspects of tumorigenesis, 
such as CAF heterogeneity, proliferation, and invasion. Notably, these studies illustrate 
how cells integrate mechanical, biochemical, and architectural cues from ECM to 
regulate their differentiation and behavior. Collectively, these findings constitute 
important advances in understanding intratumoral fibroblast heterogeneity and 
desmoplasia.  
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